


In the Matter of Impax Laboratories, Inc.
Docket No. 9373



PUBLIC

APPENDIX 1

RESPONDENT'S EXHIBIT INDEX
PURSUANT TO FTC RULE §3.46(B)

ORIGINAL

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
JX-001	Joint Stipulations of Jurisdiction, Law, Fact, and Authenticity	10/23/2017	N/A	N/A		Oct. 24, 2017 ²		Tr. 207:9 - 207:20 Tr. 1449:11 - 1449:21 Tr. 3037:11 - 3038:10	
JX-002	Joint Revised Stipulations on Admissibility of Exhibits	10/23/2017	N/A	N/A		Oct. 24, 2017 ³		Tr. 206:18 - 207:8	
CX0008	Email from Chris Mengler to Todd Engle, Larry Hsu, Meg Snowden re: Mengler Board Slides	5/14/2010	IMPAX-OPANA-CID00006693	IMPAX-OPANA-CID00006694	RX-329	JX-002 (Oct. 24, 2017)		Tr. 545:19 - 548:25	
CX0117	Email from Chris Mengler to Meg Snowden re: ENDP: Endo Pharmaceuticals Agrees to Acquire Penwest Pharmaceuticals and Submits NDA for New Formulation of Long-Acting Oxymorphone Designed to be Crush-Resistant	8/10/2010	IMPAX-OPANA-CID00012004	IMPAX-OPANA-CID00012006	RX-360	JX-002 (Oct. 24, 2017)			
CX0201	Email from Ted Smolenski to Joe Camargo, Kevin Sica, Todd Engle, et al. re: Opana ER forecast 1 of 1 w/Attach: Opana ER 1 of 1 forecast--2009-07-22.xls	7/23/2009	IMPAX-OPANA-CID00011906	IMPAX-OPANA-CID00011907	RX-567	JX-002 (Oct. 24, 2017)			
CX0202	Email from Ted Smolenski to Joe Camargo re: Opana ER forecast 1 of 1	7/30/2009	IMPAX-OPANA-CID00019479	IMPAX-OPANA-CID00019480	RX-392	JX-002 (Oct. 24, 2017)			

¹ Exhibits identified as “Non-hearsay” were “[a]dmitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted.” (See JX-002.)

² Admitted by the Court on October 24, 2017. (See Tr. 207.)

³ Admitted by the Court on October 24, 2017. (See Tr. 206–07.)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX0205	Email from Ted Smolenski to Joyce De Los Reyes, Kevin Sica, Todd Engle, et al. re: Endo: One Deal Away from Being Interesting w/Attach: ENDP--UBS--2010-02-22.pdf	2/23/2010	IMPAX-OPANA-CID00020815	IMPAX-OPANA-CID00020832	RX-396	JX-002 (Oct. 24, 2017)			
CX0214	Email from Ted Smolenski to Larry Hsu, Chris Mengler re: Research Notes - ENDO First Settlement for Generic Opana ER	2/23/2009	IMPAX-OPANA-CID00020833	IMPAX-OPANA-CID00020833	RX-397	JX-002 (Oct. 24, 2017)			
CX0217	Email from Chris Mengler to Ted Smolenski re: Oxymorphone	6/2/2010	IMPAX-OPANA-CID00019449	IMPAX-OPANA-CID00019450	RX-389	JX-002 (Oct. 24, 2017)			
CX0218	Email from Ted Smolenski to Chris Mengler re: No Subject	6/7/2010	IMPAX-OPANA-CID00019477	IMPAX-OPANA-CID00019477	RX-391	JX-002 (Oct. 24, 2017)			
CX0302	Email from Huong Nguyen to Art Koch, Meg Snowden, echoy@wsgr.com re: Draft Impax/Endo/Penwest Settlement and License Agreement w/Attach: Impax - Endo Settlement Agreement (Opana) [Execution Version].DOC	6/7/2010	IMPAX-OPANA-CID00007031	IMPAX-OPANA-CID00007057	RX-338	JX-002 (Oct. 24, 2017)			
CX0309	Email from Meg Snowden to Huong Nguyen re: Research Notes - ENDO First Settlement for Generic Opana ER w/Attach: ENDO - First Settlement for Generic Opana ER.pdf	2/23/2009	IMPAX-OPANA-CID00022178	IMPAX-OPANA-CID00022185	RX-409	JX-002 (Oct. 24, 2017)			
CX0320	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication w/Attach: Endo - Impax - Development Term Sheet (5-26-2010).DOC; Endo - Impax - Settlement Term Sheet(5-26-2010).docx	5/26/2010	IMPAX-OPANA-CID00001716	IMPAX-OPANA-CID00001726	RX-276	JX-002 (Oct. 24, 2017)		Tr. 427:4 - 430:21 Tr. 488:22 - 489:23	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX0323	Email from Guy Donatiello to Meg Snowden, Chris Mengler, Alan Levin, et al. re: <no subject> w/Attach: Draft Impax - Endo Settlement and License Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00001693	IMPAX-OPANA-CID00001715	RX-275	JX-002 (Oct. 24, 2017)			
CX0324	Email from Eliot Choy to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: 639178_Result.rtf; Impax - Endo - Rider to Settlement Agreement_(PALIB1_3993057_1).DOC; Impax - Endo - Settlement Agreement_(PALIB1_3992129_3).DOC	6/5/2010	IMPAX-OPANA-CID00001738	IMPAX-OPANA-CID00001783	RX-279	JX-002 (Oct. 24, 2017)			
CX0326	Email from Alison Freeman-Gleason to Justin Watkins, Meg Snowden, Alan Levin, et al. re: Co-Promote Revisions w/Attach: Impax-Endo_Development_and_Co-Promotion_Agreement_final.pdf; et al.	6/7/2010	IMPAX-OPANA-CID00011838	IMPAX-OPANA-CID00011904	RX-357	JX-002 (Oct. 24, 2017)			
CX0328	Email from Meg Snowden to Guy Donatiello re: Endo/Opana	10/7/2010	IMPAX-OPANA-CID00005749	IMPAX-OPANA-CID00005749	RX-314	JX-002 (Oct. 24, 2017)			
CX0329	Email from Meg Snowden to Guy Donatiello re: steering committee	12/16/2010	IMPAX-OPANA-CID00002274	IMPAX-OPANA-CID00002275	RX-286	JX-002 (Oct. 24, 2017)			
CX0330	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Caroline Manogue re: Letter from Endo to Impax Labs w/Attach: img-Z27121156-0001.pdf	12/27/2012	IMPAX-OPANA-CID00012058	IMPAX-OPANA-CID00012060	RX-361	JX-002 (Oct. 24, 2017)			
CX0332	Email from Huong Nguyen to Guy Donatiello, Meg Snowden re: Settlement and License Agreement by Endo, Penwest, and Impax ("License	1/22/2013	IMPAX-OPANA-CID00005750	IMPAX-OPANA-CID00005765	RX-315	JX-002 (Oct. 24, 2017)		Tr. 386:25 - 390:19 Tr. 490:19 - 491:18 Tr. 435:10 - 438:17	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay ¹	Discussed	In Camera Status
	Agreement") w/Attach: Copy of Endo Credit Calculation (2).xlsx; DOC.PDF								
CX0407	Email from Art Koch to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Status	6/3/2010	IMPAX-OPANA-CID00011819	IMPAX-OPANA-CID00011820	RX-356	JX-002 (Oct. 24, 2017)		Tr. 543:15 - 545:18	
CX0411	Email from Guy Donatiello to Meg Snowden, Art Koch, Alan Levin re: Revised Draft #2 w/Attach: #710157v3_BE01_ - Impax- Co-Promotion Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00006365	IMPAX-OPANA-CID00006394	RX-280	JX-002 (Oct. 24, 2017)			
CX0415	Email from Alan Levin to Art Koch, Meg Snowden, Larry Hsu, et al. re: Endo/Impax: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00001727	IMPAX-OPANA-CID00001728	RX-277	JX-002 (Oct. 24, 2017)			
CX0416	Email from Art Koch to Alan Levin, Meg Snowden, Guy Donatiello, et al. re: Gross Margin	6/6/2010	IMPAX-OPANA-CID00001815	IMPAX-OPANA-CID00001815	RX-281	JX-002 (Oct. 24, 2017)			
CX0421	Email from Chuck Hildenbrand to Art Koch re: Impax: Inventory Carrying Value - June 30, 2010 - OXM w/Attach: Oxymorphone Expiration Dates	6/21/2010	IMPAX-OPANA-CID00008018	IMPAX-OPANA-CID00008025	RX-345	JX-002 (Oct. 24, 2017)			
CX0514	Email from Chris Mengler to Larry Hsu, Art Koch, Michael Nestor, et al. re: 5-year forecast 2010-May Update with Impax.xls w/Attach: 5-year forecast 2010-May Update with Impax.xls	5/16/2010	IMPAX-OPANA-CID00006712	IMPAX-OPANA-CID00006713	RX-330	JX-002 (Oct. 24, 2017)			
CX0517	Email from Meg Snowden to Larry Hsu, Carole Ben-Maimon, Mark Donohue, et al. re: Letter from Endo to Impax Labs	12/29/2012	IMPAX-OPANA-CID00021673	IMPAX-OPANA-CID00021676	RX-404	JX-002 (Oct. 24, 2017)			
CX1001	Endo Presentation: Corporate Development Update: Endo Board of Directors Meeting	2/24/2010	EPI000821205	EPI000821205	RX-041	JX-002 (Oct. 24, 2017)		Tr. 2580:16 - 2582:14	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay ¹	Discussed	In Camera Status
CX1006	Email from Robert Cobuzzi to Kevin Pong, Alan Butcher re: IPX66 w/Attach: IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF; ATT621896.htm: 066 Apr2010AAN poster final poster.ppt; ATT621898.htm	5/20/2010	EPI001433402	EPI001433505	RX-068	JX-002 (Oct. 24, 2017)			
CX1007	Email from Robert Cobuzzi to Ernest Kopecky, Paula Clark, Frank Diana, et al. re: IPX066 w/Attach: 066 Apr2010AAN poster final poster.ppt; IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF	5/25/2010	EPI001445208	EPI001445307	RX-074	JX-002 (Oct. 24, 2017)		Tr. 2547:5 - 2549:8 Tr. 2590:11 - 2591:7 Tr. 2592:1 - 2593:4	Granted (Oct. 23, 2017) ⁴
CX1008	Email from Mark Bradley to Robert Cobuzzi re: Project Imperial	5/27/2010	EPI001433631	EPI001433638	RX-071	JX-002 (Oct. 24, 2017)		Tr. 2585:4 - 2590:10 Tr. 2591:8 - 2591:25	
CX1009	Email from Allan Miller to Robert Cobuzzi, Ellen Bernstein, David Godolphin re: Data request w/Attach: Strategic Insights.ppt	5/26/2010	EPI001433613	EPI001433618	RX-069	JX-002 (Oct. 24, 2017)			
CX1011	Email from Alan Levin to Chris Mengler, Guy Donatiello, Robert Cobuzzi re: R&D Collaboration	6/2/2010	EPI000821991	EPI000821991	RX-043	JX-002 (Oct. 24, 2017)		Tr. 2601:5 - 2602:15	
CX1015	Email from Kevin Pong to Mark Bradley, Robert Cobuzzi re: GlaxoSmithKline gains rights to Impax's experimental Parkinson's disease therapy	12/17/2010	EPI001122284	EPI001122284	RX-058	JX-002 (Oct. 24, 2017)			

⁴ See Order on Respondent's Renewed Motion for *In Camera* Treatment (Oct. 23, 2017); See also Order on *In Camera* Treatment of Respondent's Exhibits (Oct. 31, 2017).

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX1106	Email from Demir Bingol to Brian Lortie re: OPANA ER Strat. Plan w/Attach: 2010 OPANA Brand Strategic Plan-07-22-09.v7(Presentation).pptx	7/22/2009	EPI001167270	EPI001167271	RX-061	JX-002 (Oct. 24, 2017)		Tr. 2292:3 - 2293:4 Tr. 2482:3 - 2484:2	
CX1203	Email from Martin Black to Stephen Hash, Guy Donatiello re: Opana w/Attach: Document.pdf	2/20/2009	EPI000872253	EPI000872274	RX-049	JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017) ⁵
CX1209	Email from Robert Cobuzzi to rkimmel@ny.rothinc.com, JohnJDelucca@aol.com, Dave Holveck, et al. re: License with Impax Completed w/Attach: Imperial OEW final.docx	6/8/2010	EPI001448440	EPI001448457	RX-077	JX-002 (Oct. 24, 2017)		Tr. 1088:7 - 1091:20 Tr. 1122:4 - 1122:17 Tr. 1161:2 - 1163:7 Tr. 2549:9 - 2562:18 Tr. 2609:11 - 2620:22 Tr. 2622:6 - 2623:15	Granted (Oct. 23, 2017)
CX1218	Endo Document: Highlights of Opana ER Prescribing Information	5/00/2013	EPI000000451	EPI000000539	RX-006	JX-002 (Oct. 24, 2017)			
CX1220	Email from Tara Chapman to maryann.holovac@fda.hhs.gov, lisa.basham@fda.hhs.gov re: Request to move Opana ER NDA 21-610 to the Orange Book Discontinued List	5/31/2012	EPI000027305	EPI000027305	RX-008	JX-002 (Oct. 24, 2017)			
CX1305	Email from Chris Mengler to Alan Levin re: Highly Confidential - Rule 408 Settlement Communication	5/27/2010	EPI000874042	EPI000874043	RX-050	JX-002 (Oct. 24, 2017)			
CX1308	Email from Alan Levin to Chris Mengler re: <no subject>	6/3/2010	EPI000874166	EPI000874166	RX-053	JX-002 (Oct. 24, 2017)			
CX1311	Email from Alan Levin to Dave Holveck re: It's not over till the fat lady sings.....	6/4/2010	EPI002155322	EPI002155322	RX-124	JX-002 (Oct. 24, 2017)			

⁵ See Order on Non-Parties' Motions for *In Camera* Treatment (Oct. 20, 2017).

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX1403	Email from Dave Holveck to Alan Levin re: Impax--Status Update	6/1/2010	EPI001688723	EPI001688723	RX-097	JX-002 (Oct. 24, 2017)			
CX1816	Email from Guy Donatiello to Meg Snowden, Christopher Mengler, Robert Cobuzzi re: email address w/Attach: Endo Pharmaceuticals Inc. 10-13-2009.pdf	5/19/2010	EPI000828076	EPI000828079	RX-317	JX-002 (Oct. 24, 2017)		Tr. 455:12 - 456:15	
CX2504	Email from Bob Barto to Lizhuo Nouaime re: Action letter for NDA 201655 w/Attach: Complete Reponse Letter FINAL.pdf	1/10/2011	EPI000078096	EPI000078101	RX-009	JX-002 (Oct. 24, 2017)			
CX2505	Email from Tara Chapman to Ivan Gergel, Bob Barto, and Paula Clark re: OPANA ER - APPROVAL LETTER w/Attach: NDA 201655 APPROVAL letter with attachments.pdf	12/9/2011	EPI000080293	EPI000080385	RX-010	JX-002 (Oct. 24, 2017)			
CX2524	Email from Brian Lortie to Mark Bradley, Julie McHugh, and Roberto Cuca re: Data request	6/7/2010	EPI000192445	EPI000192457	RX-018	JX-002 (Oct. 24, 2017)			
CX2527	Email from Alan Levin to Mark Bradley and Karen Adler re: Impax Update	6/4/2010	EPI000874049	EPI000874049	RX-051	JX-002 (Oct. 24, 2017)			
CX2532	Email from Mark Bradley to Alan Levin, Karen Adler, Robert Cobuzzi re: Endo/Impax: R&D Collaboration	6/6/2010	EPI002156059	EPI002156061	RX-125	JX-002 (Oct. 24, 2017)			
CX2533	Email from Julie McHugh to Robert Cobuzzi, Alan Levin, Karen Adler, et al. re: Information requested	6/5/2010	EPI002156071	EPI002156074	RX-126	JX-002 (Oct. 24, 2017)			
CX2539	Email from Laura Zhu to Michael Nestor, David Paterson re: Frova, Endo w/Attach: Opana_Sales.xls	1/18/2009	IMPAX-OPANA-CID00022154	IMPAX-OPANA-CID00022156	RX-407	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2540	Email from Ted Smolenski to Joyce De Los Reyes, David Berman, Meg Snowden, et al. re: ENDP US: Endo Pharmaceuticals Holdings Inc: Tidbits from management meet... w/Attach: mbull.gif; spacer.gif	12/4/2009	IMPAX-OPANA-CID00022170	IMPAX-OPANA-CID00022171	RX-408	JX-002 (Oct. 24, 2017)		Tr. 570:16 - 581:23	
CX2557	Email from Mark Bradley to James Bradley re: EN3288/OPANA ER scenario follow up w/Attach: Topline EN3288 Forecast-06-28-10 scenarios v2.xlsx	6/30/2010	EPI000315082	EPI000315086	RX-031	JX-002 (Oct. 24, 2017)			
CX2564	Email from Mark Bradley to Roberto Cuca, David Macera, and Karen Adler re: 10 Year Outlook - New v4.xls w/Attach: 10 Year Outlook - New v4.xls	3/23/2010	EPI000180093	EPI000180094	RX-012	JX-002 (Oct. 24, 2017)			
CX2584	Email from Alison Freeman-Gleason to Meg Snowden, Michael Nestor, Shawn Fathlahi, et al. re: co-promotion agreement w/Attach: ST-#2537506-v2-Endo_co-promotion_agreement.DOC, ST-#2537507-v1-WS_comparison_Endo_co-promotion_agreement_6_June_10.DOC	6/6/2010	IMPAX-OPANA-CID00001619	IMPAX-OPANA-CID00001682	RX-274	JX-002 (Oct. 24, 2017)			
CX2594	Email from Shawn Fatholahi to Todd Engle and Carole Ben-Maimon re: Actavis' Generic Opana ER Receives FDA Approval	7/15/2013	IMPAX-OPANA-CID00007188	IMPAX-OPANA-CID00007190	RX-339	JX-002 (Oct. 24, 2017)			
CX2613	Email from Todd Engle to Shawn Fatholahi re: Actavis' Generic Opana ER Receives FDA Approval w/Attach: Graphs 07_17_13.xls	8/21/2013	IMPAX-OPANA-CID00007908	IMPAX-OPANA-CID00007914	RX-343	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2616	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication	5/26/2010	IMPAX-OPANA-CID00005625	IMPAX-OPANA-CID00005626	RX-311	JX-002 (Oct. 24, 2017)			
CX2626	Impax Document: Settlement and License Agreement	7/6/2010	Impax_Opana_PartIII_0000147	Impax_Opana_PartIII_0000172	RX-364	JX-002 (Oct. 24, 2017)		Tr. 1926:5 - 1928:13 Tr. 1934:3 - 1935:9	
CX2627	Impax Presentation: Board of Directors Meeting February 2010	2/00/2010	Impax_Opana_PartIII_0002024	Impax_Opana_PartIII_0002054	RX-150	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2628	Impax Presentation: Board of Directors Meeting November 2009	11/11/2009	Impax_Opana_PartIII_0002055	Impax_Opana_PartIII_0002090	RX-151	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2638	Email from Kimberly Kam to Steve Mollichella, Laura Bisbing, Meg Snowden re: Co-Promote Revisions w/Attach: Endo Pharmaceuticals Inc._Penwest Pharmaceuticals Settlement and License Agt 6-08-2010.pdf; Endo Pharmaceuticals Inc. Development and Co_Promotion	7/6/2010	IMPAX-OPANA-CID00012071	IMPAX-OPANA-CID00012132	RX-363	JX-002 (Oct. 24, 2017)			
CX2645	Email from Todd Engle to Carole Ben-Maimon re: Teledetailing Campaign for Oxymorphone ER	11/27/2013	IMPAX-OPANA-CID00005411	IMPAX-OPANA-CID00005411	RX-308	JX-002 (Oct. 24, 2017)			
CX2646	Email from Shawn Fatholahi to Carole Ben-Maimon, Todd Engle re: Actavis' Generic Opana ER Receives FDA Approval	7/15/2013	IMPAX-OPANA-CID00007217	IMPAX-OPANA-CID00007219	RX-341	JX-002 (Oct. 24, 2017)			
CX2654	Email from Carole Ben-Maimon to Joanne Tempone, Bryan Reasons re: Endo Deal	11/13/2012	IMPAX-OPANA-CID00019027	IMPAX-OPANA-CID00019029	RX-382	JX-002 (Oct. 24, 2017)			
CX2662	Email from Chris Mengler to Laura Bisbing, Larry Hsu, Art Koch, et al. re: Mengler Board Materials w/Attach: Tamsulosin Board May 2010 051310.ppt; BD for May BOD	5/17/2010	IMPAX-OPANA-CID00018082	IMPAX-OPANA-CID00018105	RX-374	JX-002 (Oct. 24, 2017)		Tr. 290:6 - 294:10 Tr. 335:1 - 339:1 Tr. 549:1 - 553:19	Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
	051610.ppt; Mengler Board Presentation 051610.ppt								
CX2682	Impax Presentation: Backup Slides - Impax Generic Business Board of Directors Meeting	5/13/2014	Impax_Opana_PartIII_0002298	Impax_Opana_PartIII_0002318	RX-152	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2685	Impax Presentation: Impax New Product Launches - Presentation to Board of Directors	12/10/2013	Impax_Opana_PartIII_0002381	Impax_Opana_PartIII_0002398	RX-154	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2686	Impax Presentation: Impax Generic Business Board of Directors Meeting	12/4/2012	Impax_Opana_PartIII_0002399	Impax_Opana_PartIII_0002430	RX-155	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2689	Impax Document: Minutes of a Special Meeting of the Board of Directors of Impax Laboratories, Inc.	3/28/2014	Impax_Opana_PartIII_0004163	Impax_Opana_PartIII_0004164	RX-166	JX-002 (Oct. 24, 2017)		Tr. 461:23 - 467:18	
CX2695	Impax Presentation: Dutasteride (Avodart) Launch Assessment	00/00/0000	Impax_Opana_PartIII_0004256	Impax_Opana_PartIII_0004265	RX-170	JX-002 (Oct. 24, 2017)			
CX2697	Email from Art Koch to Larry Hsu re: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00021793	IMPAX-OPANA-CID00021794	RX-212	JX-002 (Oct. 24, 2017)			
CX2701	Impax Presentation: 2010 Budget Update and 2011 Budget Preview	00/00/0000	Impax_Opana_PartIII_0003771	Impax_Opana_PartIII_0003775	RX-160	JX-002 (Oct. 24, 2017)			
CX2726	Email from Demir Bingol to Stephen McMorn, Debbie Travers, William Fiske, et al. re: EN3288-104 Topline Results	10/30/2009	EPI000209061	EPI000209062	RX-024	JX-002 (Oct. 24, 2017)			
CX2747	Email from Doug Macpherson to David Ailinger, Meg Snowden, Nancy Fetrow re: EXTERNAL: ENDO/IMPAX: Amendment to Development and Co-promotional Agreement	10/29/2015	EPI002190364	EPI002190364	RX-136	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2748	Email from Alan Levin to Mark Bradley re: Final Imperial OEW	6/8/2010	EPI002159909	EPI001379352	RX-131	JX-002 (Oct. 24, 2017)		Tr. 2544:16 - 2547:4	
CX2755	Email from Kevin Sica to Todd Engle re: Endo Opana Disclosures - FW: Charge Message Points w/Attach: Opana ER Peak Calculation for 1Q12.xls	5/2/2012	Impax_Opana_PartIII_0063864	Impax_Opana_PartIII_0063866	RX-213	JX-002 (Oct. 24, 2017)			
CX2771	Email from Thomas Rayski to Meg Snowden, Chris Mengler, Ted Smolenski, et al. re: Impax - Endo w/Attach: Draft Impax- Endo Settlement Agreement (Opana) [Endo Markup] (3).DOC; Redline - Impax-EndoSettlement and License Agreement.pdf	6/6/2010	IMPAX-OPANA-CID00006732	IMPAX-OPANA-CID00006781	RX-334	JX-002 (Oct. 24, 2017)			
CX2772	Email from Alan Levin to Karen Adler, Mark Bradley, Robert Cobuzzi re: Endo/Impax R&D Collaboration	6/6/2010	EPI001586766	EPI001586767	RX-088	JX-002 (Oct. 24, 2017)		Tr. 2540:7 - 2544:15	
CX2779	Email from Mark Bradley to Karen Adler re: Imperial valuation model w/Attach: Imperial Valuation v5.xlsx	6/5/2010	EPI002161113	EPI002161114	RX-135	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2780	Email from Robert Cobuzzi to Alan Levin, Karen Adler, Mark Bradley, et al. re: Information requested w/Attach: IPX066 Commerical Opportunity 6-4-10.ppt; Copy of IPX066 US Sales Forecast.xls; IPX-203.ppt	6/5/2010	EPI001897548	EPI001897556	RX-105, RX-106, RX-107	JX-002 (Oct. 24, 2017)			
CX2802	Email from David Macera to Robert Cooper re: Novartis manufacturing issues: Impact on Endo (RBC Report; Jan 6th)	1/6/2012	EPI001124292	EPI001124292	RX-059	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2818	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: January Forecast Submission w/Attach: Forecast Change From Previous Forecast0109.xls	1/9/2009	Impax_Opana_PartIII_0022372	Impax_Opana_PartIII_0022373	RX-180	JX-002 (Oct. 24, 2017)			
CX2819	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: June 09 Forecast Submission w/Attach: Forecast Change From Previous Forecast 0609.xls	6/5/2009	Impax_Opana_PartIII_0006077	Impax_Opana_PartIII_0006078	RX-184	JX-002 (Oct. 24, 2017)			
CX2828	Email from Joyce De Los Reyes to Joe Camargo, Kevin Sica, Chuck Hildenbrand, et al. re: Generic new product launch projection 2010-04-05.xls w/Attach: Generic new product launch projection 2010-04-05.xls	4/5/2010	IMPAX-OPANA-CID00014245	IMPAX-OPANA-CID00014246	RX-369	JX-002 (Oct. 24, 2017)			
CX2868	Email from John Anthony to Chuck Hildenbrand, Mark Shaw re: March 10 Forecast Submission w/Attach: B-2Quota2010.htm	3/9/2010	Impax_Opana_PartIII_0016249	Impax_Opana_PartIII_0016252	RX-175	JX-002 (Oct. 24, 2017)			
CX2898	Email from Joe Camargo to Todd Engle and Chuck Hildenbrand re: Launch Planning Input	5/12/2010	Impax_Opana_PartIII_0021986	Impax_Opana_PartIII_0021987	RX-179	JX-002 (Oct. 24, 2017)		Tr. 977:3 - 980:11 Tr. 1016:11 - 1017:6	
CX2901	Email from Chuck Hildenbrand to Joe Camargo re: <no subject>	5/26/2010	Impax_Opana_PartIII_0025384	Impax_Opana_PartIII_0025384	RX-182	JX-002 (Oct. 24, 2017)			
CX2904	Email from Joe Camargo to Chuck Hildenbrand, Tony Bright, Jim Larowe, et al. re: June Plan	5/25/2010	Impax_Opana_PartIII_0030026	Impax_Opana_PartIII_0030026	RX-187	JX-002 (Oct. 24, 2017)		Tr. 1017:7 - 1022:10	
CX2914	Email from Joe Camargo to Andrew Fox, Art Koch, Bob Friedel, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	6/8/2010	Impax_Opana_PartIII_0077849	Impax_Opana_PartIII_0077850	RX-226	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2922	Email from Willi Huang to Ray Smith, Shan Gao, Joe Camargo, et al. re: At Risk Inventory report for March 2011 w/Attach: At Risk Inventory March 11 R0.xls	4/1/2011	Impax_Opana_PartIII_0005732	Impax_Opana_PartIII_0005733		JX-002 (Oct. 24, 2017)		Tr. 1024:16 - 1033:7	
CX2929	Email from Larry Hsu to Chuck Hildenbrand, Chris Mengler, Art Koch, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/14/2010	Impax_Opana_PartIII_0044621	Impax_Opana_PartIII_0044622	RX-195	JX-002 (Oct. 24, 2017)		Tr. 308:19 - 310:22 Tr. 355:15 - 357:2 Tr. 584:4 - 585:16	
CX2930	Email from Meg Snowden to Art Koch, Larry Hsu, Michael Nestor, et al. re: Highly Confidential - Rule 408 Settlement Communication w/Attach: Endo - Impax - Development Term Sheet (5-26-2010).DOC; Endo - Impax - Settlement Term Sheet (5-26-2010).docx	5/26/2010	IMPAX-OPANA-CID00006719	IMPAX-OPANA-CID00006729	RX-331	JX-002 (Oct. 24, 2017)		Tr. 3016:5 - 3017:15	
CX2933	Meeting Scheduler re: Co-Promote Teleconference with Attendees: Brian Lortie, Alan Levin, Robert Cobuzzi, Meg Snowden, et al.	6/7/2010	IMPAX-OPANA-CID00006143	IMPAX-OPANA-CID00006143	RX-326	JX-002 (Oct. 24, 2017)			
CX2948	Email from Suneel Gupta to Michael Nestor re: Endo contact person	6/3/2010	IMPAX-OPANA-CID00001599	IMPAX-OPANA-CID00001599	RX-269	JX-002 (Oct. 24, 2017)			
CX2949	Email from Robert Cobuzzi to Michael Nestor, Chris Mengler, Alan Levin re: R&D Contact?	6/4/2010	IMPAX-OPANA-CID00001611	IMPAX-OPANA-CID00001612	RX-273	JX-002 (Oct. 24, 2017)			
CX2953	Email from Bryan Reasons to Michael Nestor, Suneel Gupta re: Impax/Endo Development and Co-Promotion Agreement Milestones w/Attach: image001.png; image002.png	4/16/2013	IMPAX-OPANA-CID00007983	IMPAX-OPANA-CID00007987	RX-344	JX-002 (Oct. 24, 2017)			
CX2954	Email from Suneel Gupta to Steve Mollichella, Meg Snowden, Michael Nestor re: Co-Promote Revisions	7/1/2010	IMPAX-OPANA-CID00011919	IMPAX-OPANA-CID00011923	RX-358	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX2955	Email from Michael Nestor to Suneel Gupta re: BoD slides w/Attach: BOD draft ver3.ppt	8/1/2010	IMPAX-OPANA-CID00012655	IMPAX-OPANA-CID00012699	RX-368	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX2956	Email from Michael Nestor to Brandon Smith re: Slide format w/Attach: BOD 07092013.ppt	7/5/2013	IMPAX-OPANA-CID00016072	IMPAX-OPANA-CID00016091	RX-370	JX-002 (Oct. 24, 2017)		Tr. 2958:1 - 2963:24 Tr. 3039:5 - 3041:24	Granted (Oct. 23, 2017)
CX2962	Email from Meg Snowden to Michael Nestor, Shawn Fatholahi, Suneel Gupta, et al. re: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00021838	IMPAX-OPANA-CID00021839	RX-569	JX-002 (Oct. 24, 2017)			
CX2964	Email from Jennifer Saionz to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: Impax inserts_(PAU 81_3993075_1).DOC	6/6/2010	IMPAX-OPANA-CID00001416	IMPAX-OPANA-CID00001438	RX-267	JX-002 (Oct. 24, 2017)			
CX2966	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Chris Mengler, and Meg Snowden re: IPX066 w/Attach: 066 Apr2010AAN poster final poster.ppt, IPX066_IMPAX_Partner_Confidential_032010_FINAL.pdf	5/19/2010	IMPAX-OPANA-CID00001974	IMPAX-OPANA-CID00002103	RX-284	JX-002 (Oct. 24, 2017)			
CX2967	Email from Sibel Ucpinar to Todd Engle re: Opana ER volume 1 of 5 w/Attach: 2007-06-25 79-087 Original ANDA vol 1 of 7.pdf	10/17/2012	IMPAX-OPANA-CID00009918	IMPAX-OPANA-CID00010400	RX-349	JX-002 (Oct. 24, 2017)			
CX2975	Actavis Spreadsheet: Oxymorphone ER August 2013	12/17/2013	Actavis_FTC_Opana_000379	Actavis_FTC_Opana_000379	RX-001	JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
CX2986	Email from Suneel Gupta to Adrienne Ford, Bryan Reasons, Michael Nestor, et al. re: Impax/Endo Development and Co-Promotion Agreement Milestones	10/29/2013	IMPAX-OPANA-CID00005538	IMPAX-OPANA-CID00005539	RX-309	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX3017	Email from Brian Hogan to Roberto Cuca, Lee Lenkner re: Opana ER / IR P&L Scenario Model w/Attach: OPANA Brand P&L Model Scenarios - Generic launch v3.xlsx	5/28/2010	EPI001588856	EPI001588859		JX-002 (Oct. 24, 2017)		Tr. 645:16 - 658:25	
CX3025	Email from Alan Levin to Roberto Cuca re: Impax - Endo	6/7/2010	EPI001688925	EPI001688926	RX-098	JX-002 (Oct. 24, 2017)			
CX3048	Email from Roberto Cuca to Todd Engle, Carrie Cooper re: Steering Committee w/Attach: IMPAX Prescription Sales and Quarterly Peak Calculations July 2010 - Dec 2011.xlsx	3/7/2012	IMPAX-OPANA-CID00005714	IMPAX-OPANA-CID00005717	RX-313	JX-002 (Oct. 24, 2017)			
CX3063	Email from Joe Camargo to Chuck Hildenbrand, Chris Mengler, and Todd Engle re: March 10 Forecast Submission	3/9/2010	Impax_Opana_PartIII_0018507	Impax_Opana_PartIII_0018509	RX-177	JX-002 (Oct. 24, 2017)			
CX3092	Email from Steve Mollichella to Kevin Sica, Todd Engle re: ENDO Payment Calculation w/Attach: Opana ER Peak Calculation for 4Q12 R1 with IMS data.xls	1/29/2013	Impax_Opana_PartIII_0063870	Impax_Opana_PartIII_0063871	RX-215	JX-002 (Oct. 24, 2017)			
CX3105	Email from Larry Kloss to Bryan Reasons and George Hill re: 7 Year Plan Summary - 9-9-14 - Update (ALTERNATE w/o IPX 203) w/Attach: 7 Year Plan Summary - 9-9-14 - Update.xlsx	9/8/2014	Impax_Opana_PartIII_0058604	Impax_Opana_PartIII_0058605	RX-203	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX3106	Email from Larry Kloss to Michael Nestor re: IPX203 Financial (Base) Forecast w/Attach: IPX203 Project Timeline_costing (Base_Optimistic)_14Aug2015.potx, IPX203 Operational (Optimistic)	8/15/2015	Impax_Opana_PartIII_0063716	Impax_Opana_PartIII_0063725	RX-210	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
	Forecast 2015-08-14.xlsx, IPX203 Operational (Optimistic) Forecast...								
CX3111	Email from Joyce de los Reyes to Richard Ting and April Isaacson re: PEC meeting (9AM PT/ 12PM ET) w/Attach: PEC 2015-07-02.pptx	7/2/2015	Impax_Opana_PartIII_0081075	Impax_Opana_PartIII_0081123	RX-239	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX3117	Email from Jeff Miller to Timothy Niedrist re: Update Requested => Impax-Endo Agreement w/Attach: Update Requested => Impax-Endo Agreement	7/2/2012	IMPAX-OPANA-CID00011740	IMPAX-OPANA-CID00011754	RX-355	JX-002 (Oct. 24, 2017)			
CX3130	Email from Roberto Cuca to Alan Levin, Darnell Turner, and David Macera re: Per share price impact of generic Opana ER launch	3/15/2010	EPI002159607	EPI001588193	RX-130	JX-002 (Oct. 24, 2017)			
CX3187	Email from Larry Hsu to Ted Smolenski, Art Koch re: opana ER	1/8/2011	IMPAX-OPANA-CID00003557	IMPAX-OPANA-CID00003558	RX-293	JX-002 (Oct. 24, 2017)			
CX3203	Email from Brian Risk to Brian Munroe re: Letter to FDA and Opana Citizens Petitions w/Attach: Date-Stamped Opana ER CP 31 Aug 2012.pdf; Endo CP Submission (8-13-12) date-stamped.pdf; Coalition letter to FDA re ADF conditions 101812.pdf	10/18/2012	EPI001180038	EPI001180099	RX-065	JX-002 (Oct. 24, 2017)		Tr. 477:3 - 481:13	
CX3215	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2012	3/1/2013	CX3215-001	CX3215-355	RX-496	JX-002 (Oct. 24, 2017)			
CX3222	Impax Presentation: Board of Directors Meeting May 2010	5/00/2010	Impax_Opana_PartIII_0003917	Impax_Opana_PartIII_0003939	RX-163	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
CX3223	Impax Document: Minutes of a Special Meeting of the Board of Directors of Impax Laboratories, Inc.	7/5/2013	Impax_Opana_PartIII_0004183	Impax_Opana_PartIII_0004184	RX-168	JX-002 (Oct. 24, 2017)		Tr. 467:19 - 470:1	
CX3273	Document: Declaration of Demir Bingol, Civil Action Nos. 09-cv-831 (KSH) (PS), 09-cv-832 (KSH) (PS), 09-cv-833 (KSH) (PS)	5/21/2010	CX3273-001	CX3273-010	RX-486	JX-002 (Oct. 24, 2017)		Tr. 1280:22 - 1286:16 Tr. 1287:22 - 1293:8 Tr. 1315:22 - 1319:9	
CX3278	Impax Annual Report 2010 (December 31, 2010 SEC Form 10-K)	2/25/2011	CX3278-001	CX3278-144		JX-002 (Oct. 24, 2017)		Tr. 267:14 - 274:5	
CX3281	Actavis Spreadsheet: NPA Opioids 2014-10-07	10/9/2014	ACTLID00216620	ACTLID00220254	RX-005	JX-002 (Oct. 24, 2017)			
CX3296	Impax Spreadsheet: Monthly Module Views- Rx (NPA)_1_Apr-30-2017	5/8/2017	Impax_Opana_PartIII_0002021	Impax_Opana_PartIII_0002021	RX-149	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
CX3329	Email from Danielle Morelli to Andrew Fox, Tim Jones re: Oxymorphone	6/1/2011	IMPAX-OPANA-CID00020787	IMPAX-OPANA-CID00020792	RX-395	JX-002 (Oct. 24, 2017)			
CX3345	Email from David Ailinger to David Paterson, Suneel Gupta, Michael Nestor re: Endo IPX-203 w/Attach: Endo08072015.ppt	8/7/2015	Impax_Opana_PartIII_0063726	Impax_Opana_PartIII_0063735	RX-211	JX-002 (Oct. 24, 2017)		Tr. 2967:8 - 2969:6	Granted (Oct. 23, 2017)
CX3347	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting Background Documentation w/AttachL launch planning 02 02 10 R2.doc	2/2/2010	Impax_Opana_PartIII_0044547	Impax_Opana_PartIII_0044571	RX-194	JX-002 (Oct. 24, 2017)		Tr. 1751:8 - 1755:7 Tr. 1771:23 - 1775:8 Tr. 1788:19 - 1789:14	
CX3348	Email from Todd Engle to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Quarterly Launch Planning Meeting May 20, 2010 Agenda Materials w/Attach: QLPM 052010.doc	5/20/2010	Impax_Opana_PartIII_0069160	Impax_Opana_PartIII_0069201	RX-216	JX-002 (Oct. 24, 2017)		Tr. 556:7 - 558:25 Tr. 1755:8 - 1759:11 Tr. 1775:9 - 1777:12 Tr. 1789:15 - 1791:18	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX3349	Email from Art Koch to Alan Levin, Meg Snowden, Michael Nestor, et al. re: <no subject>	6/6/2010	IMPAX-OPANA-CID00001411	IMPAX-OPANA-CID00001412	RX-042	JX-002 (Oct. 24, 2017)			
CX3437	Case 2:16-cv-02526-JLL-JAD: Amended Complaint	8/1/2016	CX3437-001	CX3437-163		JX-002 (Oct. 24, 2017)	Non-hearsay	Tr. 2083:7 - 2096:16 Tr. 2892:10 - 2897:18	
CX3449	Impax Document: Paragraph IV Patent Certification: 5,662,933	N/A	IMPAX-OPANA-CID00000017	IMPAX-OPANA-CID00000018	RX-466	JX-002 (Oct. 24, 2017)			
CX3450	Impax Document: Paragraph IV Patent Certification: 5,958,456	N/A	IMPAX-OPANA-CID00000019	IMPAX-OPANA-CID00000020	RX-265	JX-002 (Oct. 24, 2017)			
CX4002	IH Transcript: Theodore Smolenski (Impax)	9/30/2014	CX4002-001	CX4002-088		JX-002 (Oct. 24, 2017)		Tr. 1657:2 - 1660:7	
CX4005	IH Transcript: Alan Levin (Endo) Day 1	11/13/2014	CX4005-001	CX4005-075	RX-516	JX-002 (Oct. 24, 2017)			
CX4006	IH Transcript: Alan Levin (Endo) Day 2	11/14/2014	CX4006-001	CX4006-058	RX-517	JX-002 (Oct. 24, 2017)			
CX4007	IH Transcript: Brian Lortie (Endo)	9/18/2014	CX4007-001	CX4007-108	RX-505	JX-002 (Oct. 24, 2017)			
CX4008	IH Transcript: Caroline Manogue (Endo) Day 1	9/25/2014	CX4008-001	CX4008-087	RX-506	JX-002 (Oct. 24, 2017)			
CX4009	IH Transcript: Caroline Manogue (Endo) Day 2	12/2/2014	CX4009-001	CX4009-070	RX-520	JX-002 (Oct. 24, 2017)			
CX4011	IH Transcript: David Holveck (Endo)	11/18/2014	CX4011-001	CX4011-098	RX-518	JX-002 (Oct. 24, 2017)			
CX4013	IH Transcript: Kevin Pong, Ph.D. (Endo)	12/4/2014	CX4013-001	CX4013-082	RX-521	JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX4015	IH Transcript: Robert Barto (Endo)	11/25/2014	CX4015-001	CX4015-082	RX-519	JX-002 (Oct. 24, 2017)			
CX4016	IH Transcript: Robert Cobuzzi (Endo)	9/11/2014	CX4016-001	CX4016-122		JX-002 (Oct. 24, 2017)		Tr. 1170:4 - 1172:6 Tr. 1187:14 - 1190:21 Tr. 2577:7 - 2578:18	
CX4017	Deposition Transcript: Alan Levin (Endo)	8/10/2017	CX4017-001	CX4017-074	RX-543	JX-002 (Oct. 24, 2017)			
CX4018	Deposition Transcript: Arthur A. Koch, Jr. (Impax)	6/6/2017	CX4018-001	CX4018-061		JX-002 (Oct. 24, 2017)		Tr. 239:15 - 241:17	
CX4024	Deposition Transcript: David Macera (Endo)	7/12/2017	CX4024-001	CX4024-067	RX-537	JX-002 (Oct. 24, 2017)			
CX4026	Deposition Transcript: Huong Nguyen (Impax)	6/29/2017	CX4026-001	CX4026-079	RX-535	JX-002 (Oct. 24, 2017)			
CX4029	Deposition Transcript: Kevin Sica (Impax)	8/8/2017	CX4029-001	CX4029-044	RX-542	JX-002 (Oct. 24, 2017)			
CX4031	Deposition Transcript: Mark Bradley (Endo)	7/6/2017	CX4031-001	CX4031-076	RX-536	JX-002 (Oct. 24, 2017)			
CX4034	Deposition Transcript: Richard Rogerson (Actavis)	8/4/2017	CX4034-001	CX4034-043	RX-541	JX-002 (Oct. 24, 2017)			
CX4036	Deposition Transcript: Shawn Fatholahi (Impax)	5/23/2017	CX4036-001	CX4036-066	RX-533	JX-002 (Oct. 24, 2017)			
CX4039	RESERVED: Deposition Transcript: Roger G. Noll	00/00/0000	CX4039-001	CX4039-001		JX-002 (Oct. 24, 2017)		Tr. 1666:7 - 1666:22	
CX4040	RESERVED: Deposition Transcript: Max H. Bazerman	00/00/0000	CX4040-001	CX4040-001		JX-002 (Oct. 24, 2017)		Tr. 909:10 - 910:14	
CX4042	RESERVED: Deposition Transcript: John Geltosky	00/00/0000	CX4042-001	CX4042-001		JX-002 (Oct. 24, 2017)		Tr. 1142:14 - 1143:23 Tr. 1150:11 - 1151:18 Tr. 1152:15 - 1153:12	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
CX5000	Expert Report: Roger G. Noll	8/25/2017	CX5000-001	CX5000-292		JX-002 (Oct. 24, 2017)		Tr. 1424:10 - 1427:7 Tr. 1469:24 - 1482:23 Tr. 1536:15 - 1537:11 Tr. 1631:5 - 1632:21 Tr. 1633:10 - 1642:17 Tr. 1650:7 - 1656:17 Tr. 1677:15 - 1685:2	Granted (Nov. 28, 2017) ⁶
CX5002	Expert Report: Seddon R. Savage	8/25/2017	CX5002-001	CX5002-106		JX-002 (Oct. 24, 2017)		Tr. 705:22 - 709:1 Tr. 727:14 - 743:23 Tr. 805:24 - 809:21 Tr. 2188:25 - 2193:17	
CX5003	Expert Report: John Geltosky	8/25/2017	CX5003-001	CX5003-070		JX-002 (Oct. 24, 2017)		Tr. 1117:21 - 1119:15 Tr. 1130:5 - 1131:23	
CX5004	Rebuttal Expert Report: Roger G. Noll	9/20/2017	CX5004-001	CX5004-117		JX-002 (Oct. 24, 2017)		Tr. 1515:4 - 1517:19	
CX5007	Rebuttal Expert Report: Thomas Hoxie	9/20/2017	CX5007-001	CX5007-053		JX-002 (Oct. 24, 2017)		Tr. 2764:20 - 2766:9 Tr. 2819:14 - 2820:11	
RX-002	Pricing and Sales Spreadsheet (Aug. 2013)	08/01/2013	Actavis_FTC_Opana_000380	Actavis_FTC_Opana_000380		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-003	Settlement and License Agreement (Feb. 20, 2009)	02/20/2009	ACTLID00049662	ACTLID00049683		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-004	Settlement and License Agreement (Undated)		ACTLID00091291	ACTLID00091309		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-007	Endo Presentation, Revopan (3Q 2010)	09/30/2010	EPI000005189	EPI000005208		JX-002 (Oct. 24, 2017)			

⁶ Order on IQVIA's Motion for *In Camera* Treatment (Nov. 28, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-011	Letter from B. Rappaport, M.D. to R. Barto (Jan. 7, 2011)	01/07/2011	EPI000159427	EPI000159431		JX-002 (Oct. 24, 2017)			
RX-013	Email from S. Kang to A. Salamon re: Endo Generics_Weekly Report_(week ending 5.14.10)(May 24, 2010)	05/24/2010	EPI000180178	EPI000180178		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-014	Email from S. Oehler to R. Cuca, et al., FW: APPROVAL NEEDED - Prime Part D- 3rd Amendment, with attachments (June 29, 2011)	06/29/2011	EPI000181590	EPI000181599		JX-002 (Oct. 24, 2017)		Tr. 2293:5 - 2295:24	
RX-015	Email from R. DAnnibale to K. Vitanza, et al., Opana ER Preparation Meeting: Final Analytics Deck Updated, with attachments (June 18, 2012)	06/18/2012	EPI000187892	EPI000187896		JX-002 (Oct. 24, 2017)			
RX-016	Email from K. Vitanza to J. Goldsmith, et al., Here are the slides from the Julie Meeting... minus the forecast scenarios... once approved we can share with you, with attachment (June 20, 2012)	06/20/2012	EPI000187897	EPI000187899		JX-002 (Oct. 24, 2017)			
RX-017	Email from K. O'Brien to B. Lortie, et al., OER Bullett Points (Oct. 24, 2013), with attachment	10/24/2013	EPI000192076	EPI000192077		JX-002 (Oct. 24, 2017)			
RX-019	Data request (Aug. 7, 2010)	08/07/2010	EPI000192458	EPI000192470		JX-002 (Oct. 24, 2017)			
RX-020	Opana ER Q2 2012 Quarterly Business Review (July 24, 2012)	07/24/2012	EPI000194441	EPI000194441		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-021	Fifth Amendment to the Manufacturer's Medicare Discount Agreement Between Aetna Health Management, LLC and Endo Pharmaceuticals, Inc. (Oct. 18, 2010)	10/18/2010	EPI000200473	EPI000200480		JX-002 (Oct. 24, 2017)		Tr. 2296:1 - 2300:11	Granted (Oct. 20, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-022	Sixth Amendment to the Manufacturer's Medicare Discount Agreement Between Aetna Health Management, LLC and Endo Pharmaceuticals, Inc. (Nov. 11, 2011)	11/11/2011	EPI000200481	EPI000200487		JX-002 (Oct. 24, 2017)		Tr. 2300:12 - 2301:11	Granted (Oct. 20, 2017)
RX-023	Email from K. Zubey to R. Mastrangelo, et. al, Does Kara work at Endo anymore?, with attachment (Apr. 2, 2013)	04/02/2013	EPI000205306	EPI000205308		JX-002 (Oct. 24, 2017)		Tr. 2274:15 - 2275:24 Tr. 2290:23 - 2292:1	
RX-025	Bioequivalence Study of Single, Intact, 40 mg Tablets of Oxymorphone Extended Release and Crush- Resistant Oxymorphone Extended Release in Fasting Healthy Volunteers		EPI000218098	EPI000218098		JX-002 (Oct. 24, 2017)			
RX-026	Lidoderm Executive Summary		EPI000286431	EPI000286440		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-027	Endo Executive Summary DRAFT (Q1 2010)	03/31/2010	EPI000286447	EPI000286450		JX-002 (Oct. 24, 2017)			
RX-028	Background: OPANA® Franchise (Jan. 30, 2008)	01/30/2008	EPI000286519	EPI000286540		JX-002 (Oct. 24, 2017)		Tr. 2279:24 - 2282:15	Granted (Oct. 20, 2017)
RX-029	Endo Presentation, New and Potential Competitors in the Long-Acting Opioid Market		EPI000286665	EPI000286665		JX-002 (Oct. 24, 2017)			
RX-030	Highlights of Prescribing Information (Apr. 2011)	04/01/2011	EPI000289905	EPI000289933		JX-002 (Oct. 24, 2017)		Tr. 2239:18 - 2240:23	
RX-032	Revopan Presentation, Revopan Playbook		EPI000319916	EPI000319916		JX-002 (Oct. 24, 2017)			
RX-033	Email from D. Bingol to A. Levin re: Competitor Chart (Oct. 10, 2009), with attachments	10/10/2009	EPI000422155	EPI000422157		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-034	Endo Memorandum from C. Vainstein to Files re: Considerations related to Returns Reserve Balance for the OpanaER Family as of December 31, 2011 (Dec. 31, 2011)	12/31/2011	EPI000475211	EPI000475213		JX-002 (Oct. 24, 2017)			
RX-035	Email from D. Rudio to A. Levin, et al., Impax (Apr. 21, 2012)	04/21/2012	EPI000475451	EPI000575451		JX-002 (Oct. 24, 2017)			
RX-036	Email from N. Shusterman to I. Gergel, et al., re: EN3288: October 21/22 FDA Advisory Committee Meeting (Note 2 of 3) (Oct. 24, 2010)	10/24/2010	EPI000569175	EPI000569176		JX-002 (Oct. 24, 2017)			
RX-037	Prescription Sales Of Endo Products (Q4 2012)	12/31/2012	EPI000594258	EPI000594258		JX-002 (Oct. 24, 2017)			
RX-038	Email from A. Levin to D. Rudio re: Follow-ups on our Q1 Update Meeting from Yesterday (Apr. 17, 2012)	04/17/2012	EPI000610953	EPI000610954		JX-002 (Oct. 24, 2017)			
RX-039	Email from A. Levin to D. Rudio, et al., Re: Opana ER data (Apr. 24, 2012)	04/24/2012	EPI000611033	EPI000611039		JX-002 (Oct. 24, 2017)			
RX-040	Background: OPANA® Franchise (July 9, 2008)	07/09/2008	EPI000764555	EPI000764563		JX-002 (Oct. 24, 2017)		Tr. 2268:6 - 2270:21	Granted (Oct. 20, 2017)
RX-044	Email from G. Donatiello to M. Black re: FW: Endo/Sandoz Confidential Settlement Term Sheet - Rule 408 Communication(May 17, 2010)	05/17/2010	EPI000828069	EPI000828070		JX-002 (Oct. 24, 2017)			
RX-045	Non-Binding Term Sheet - DRAFT (May 17, 2010)	05/17/2010	EPI000828071	EPI000828075		JX-002 (Oct. 24, 2017)			
RX-046	Letter from Dechert LLP to FTC re: Filing Pursuant to Section 1112(a)-Disclosure Exemption Requested (June 18, 2010)	06/18/2010	EPI000828740	EPI000828801		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-047	Email from T. Rayski to J. Lee, et al., RE: Executed Sig pages, with attachments (Mar. 21, 2012)	03/21/2012	EPI000831243	EPI000831290		JX-002 (Oct. 24, 2017)			
RX-048	Email from A. Analla to R. Jackson re: Opioid Market Roll Up of 4-9-10 IMS Data (Apr. 24, 2010)	04/24/2010	EPI000852068	EPI000852070		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-052	Email from A. Levin to A. Koch, Re: Gross Margin (June 7, 2010)	06/07/2010	EPI000874093	EPI000874094		JX-002 (Oct. 24, 2017)			
RX-054	Endo Presentation, Paris Valuation (July 1, 2010)	07/01/2010	EPI000874355	EPI000874362		JX-002 (Oct. 24, 2017)			
RX-055	Email from M. Wieman to T. Chapman, RE: EN328B - NDA RESUBMISSION - submitted today (June 13, 2011)	06/13/2011	EPI000961110	EPI000961110		JX-002 (Oct. 24, 2017)			
RX-056	Email from D. Bingol to B. Lortie, FW: CONFIDENTIAL - EN3288 (Aug. 3, 2010)	08/03/2010	EPI000976739	EPI000976740		JX-002 (Oct. 24, 2017)			
RX-057	Letter from Endo to Healthcare Professionals re: Letter Regarding Potential Endo Product Supply Disruption and Possibility of Rare Tablet Mix-Up (Jan. 9, 2012)	01/09/2012	EPI001065982	EPI001065982		JX-002 (Oct. 24, 2017)			
RX-060	Email from G. Pyszcymuka to K. Vitanza, et al., DRAFT - Opana ER Selected Opportunities (7-30- 12).ppt (July 30, 2012)	07/30/2012	EPI001165531	EPI001165532		JX-002 (Oct. 24, 2017)			
RX-062	Endo Presentation, Financial Review: Board of Directors Meeting - Compensation Committee (Feb. 23, 2010)	02/23/2010	EPI001172034	EPI001172034		JX-002 (Oct. 24, 2017)			
RX-063	Email from B. Munroe to B. Munroe, Endo meeting with the DEA (Oct. 7, 2011), with attachments	10/07/2011	EPI001179292	EPI001179300		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-064	Letter from S. Cowan to Dr. C. Sannerud (Oct. 6, 2011)	10/06/2011	EPI001179295	EPI001179299		JX-002 (Oct. 24, 2017)			
RX-066	Email from E. Keane to L. Romaine, FW: OER ISC Redemptions (Aug. 1, 2010), with attachment	08/01/2010	EPI001228672	EPI001228674		JX-002 (Oct. 24, 2017)		Tr. 2282:16 - 2284:12	
RX-067	Endo Presentation, 2009 OPANA Brand Plan DRAFT		EPI001296710	EPI001296710		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-070	Parkinson's Disease Opportunity IPX066, Strategic Insights (May 26, 2010)	05/26/2010	EPI001433618	EPI001433618		JX-002 (Oct. 24, 2017)			
RX-072	Email from D. Godolphin to R. Cobuzzi, et al., RE: Data request (May 24, 2010)	05/24/2010	EPI001433682	EPI001433687		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-073	Email from R. Mastrangelo to K. Marv, et al., RE: FINAL Opana ER CEO deck_final 4-8-14.pptx, with attachments (Apr. 11, 2013)	04/11/2013	EPI001440246	EPI001440260		JX-002 (Oct. 24, 2017)		Tr. 2262:3 - 2264:18	
RX-075	Email from M. Bradley to K. Pong, et al., re: Imperial OEW (May 28, 2010), with attachments	05/28/2010	EPI001448375	EPI001448387		JX-002 (Oct. 24, 2017)			
RX-076	Opportunity Evaluation Worksheet (OEW) (June 2009)	06/01/2009	EPI001448406	EPI001448421		JX-002 (Oct. 24, 2017)			
RX-078	Presentation, Revopan TM Launch Readiness Review (Dec. 16, 2010)	12/16/2010	EPI001449529	EPI001449529		JX-002 (Oct. 24, 2017)		Tr. 2260:19 - 2262:2	
RX-079	Opportunity Evaluation Worksheet (OEW) (June 2009)	06/01/2009	EPI001454170	EPI001454186		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-080	Opportunity Evaluation Workshet, IPX-203		EPI001454188	EPI001454204		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-081	Opportunity Evaluation Worksheet (OEW) (June 2009)	06/01/2009	EPI001454208	EPI001454224		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-082	Endo Presentation, OpanaER Customer Plan (Sept. 2011)	09/01/2011	EPI001480565	EPI001480565		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-083	Email from L. Lenkner to K. Vitanza, RE: 2012 Budget Spend (Sept. 28, 2011), with attachment	09/28/2011	EPI001480577	EPI001480579		JX-002 (Oct. 24, 2017)			
RX-084	Background: OPANA Franchise (July 9, 2008)	07/09/2008	EPI001538013	EPI001538021		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-085	Endo Presentation, 2008-2012 OPANA Brand Single Strategy Plan (June 29, 2007)	06/29/2007	EPI001538036	EPI001538036		JX-002 (Oct. 24, 2017)		Tr. 2270:22 - 2274:13 Tr. 2257:11 - 2258:24	Granted (Oct. 20, 2017)
RX-086	Endo Presentation, Opioid Pain Marketplace Assessment: Final Generic Opioid Marketplace Report (June 8, 2010)	06/08/2010	EPI001553390	EPI001553390		JX-002 (Oct. 24, 2017)		Tr. 1329:25 - 1336:18 Tr. 2808:19 - 2816:24 Tr. 2905:19 - 2907:9	
RX-087	UPMC Health Plan, Impact of an OxyContin® Formulary Change on Member Opioid Utilization and Prescriber Practice		EPI001558574	EPI001558574		JX-002 (Oct. 24, 2017)		Tr. 1554:3 - 1564:3 Tr. 2302:13 - 2309:22	
RX-089	Bank of America Merrill Lynch, Price Objective Change: Raising PO to \$27 (Mar. 15, 2010)	03/15/2010	EPI001588173	EPI001588192		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-093	Endo Presentation, Novartis Supply Interruption Update		EPI001595190	EPI001595190		JX-002 (Oct. 24, 2017)			
RX-094	Email from D. Rudio to K. Adler, et al., re: Impax Memo and Calculation Coming Soon? (Apr. 20, 2012), with attachments	04/20/2012	EPI001595260	EPI001595265		JX-002 (Oct. 24, 2017)			
RX-095	Endo Memorandum from D. Rudio to Files re: Impax Settlement Payment - Accounting Considerations - DRAFT		EPI001595261	EPI001595265		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-096	Key Messages: Endo Top of Mind Topics		EPI001659890	EPI001659920		JX-002 (Oct. 24, 2017)			
RX-100	Email from J. Wahlert to D. Rudio, et al., re: Impax Draft (Apr. 23, 2012)	04/23/2012	EPI001719102	EPI001719103		JX-002 (Oct. 24, 2017)			
RX-101	Letter from Deloitte & Touche to Endo re: Review of Unaudited Condensed Consolidated Balance Sheets (May 1, 2012)	05/01/2012	EPI001720621	EPI001720637		JX-002 (Oct. 24, 2017)			
RX-102	Email from K. Dougherty to G. Donatiello, et al., RE: my info. - Johnson Mattley (Oct. 26, 2009)	10/26/2009	EPI001747842	EPI001747846		JX-002 (Oct. 24, 2017)			
RX-103	Email from M. Bradley to D. Bingol re: Opana Scenarios (Feb. 21, 2011)	02/21/2011	EPI001768206	EPI001768209		JX-002 (Oct. 24, 2017)			
RX-104	Draft of Opana ER Demand Justification (2010)		EPI001773316	EPI001773318		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-108	Email from A. Levin to C. Cary, et al., April 16 ELC Meeting: Finance Update Pre-Read Materials (Apr. 12, 2012), with attachments	04/12/2012	EPI001906463	EPI001906469		JX-002 (Oct. 24, 2017)			
RX-109	Endo Presentation, 1Q12 Financial Results & FY 2012 Forecast: Board of Directors Meeting (Apr. 25, 2012)	04/25/2012	EPI001906464	EPI001906464		JX-002 (Oct. 24, 2017)			
RX-110	Email from K. Marv to J. Yankovich, et al., Opana ER CEO deck_final 4-8-14.pptx (Apr. 8, 2013), with attachment	04/08/2013	EPI00191622	EPI00191623		JX-002 (Oct. 24, 2017)			
RX-111	Endo Presentation, OpanaER Customer Plan (Sept. 2011)	09/01/2011	EPI001919288	EPI001919288		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-112	Endo Presentation, OPANA ER - Situation Analysis Marketing Science: "Insights to Impact" (June 2009)	06/01/2009	EPI001923490	EPI001923490		JX-002 (Oct. 24, 2017)		Tr. 2259:1 - 2260:17	Granted (Oct. 20, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-113	Fax from J. Rannazzisi to C. Beaver (Oct. 18, 2011)	10/18/2011	EPI001927350	EPI001927350		JX-002 (Oct. 24, 2017)			
RX-114	Endo Pharmaceuticals, Oxymorphone Franchise Business Plan 2011 thru 2021 (June 3, 2010)	06/03/2010	EPI002016437	EPI002016437		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-115	OpanaER Playbook (2Q 2011)	06/30/2011	EPI002018090	EPI002018090		JX-002 (Oct. 24, 2017)			
RX-116	DRAFT of 10-Q Changes		EPI002072835	EPI002072852		JX-002 (Oct. 24, 2017)			
RX-117	Endo Pharmaceuticals Holdings Inc., Form 10-Q (Mar. 31, 2012)	03/31/2012	EPI002073289	EPI002073364		JX-002 (Oct. 24, 2017)			
RX-118	Endo Memorandum to Members of the Audit Committee of the Board of Directors re: Summary of Significant Changes Made to 10-Q Subsequent to Posting to Diligent on Apr. 18, 2012	04/18/2012	EPI002073496	EPI002073507		JX-002 (Oct. 24, 2017)			
RX-119	Questions & Answers v2		EPI002075612	EPI002075640		JX-002 (Oct. 24, 2017)		Tr. 2285:16 - 2286:22	
RX-120	Inspiring Outcomes Presentation, Opana® ER Brand Overview for in Ventiv Agency Partners (Oct. 3, 2011)	10/03/2011	EPI002117839	EPI002117839		JX-002 (Oct. 24, 2017)			
RX-122	Opana® ER Product Level Set (Apr. 2011)	04/01/2011	EPI002128951	EPI002128951		JX-002 (Oct. 24, 2017)		Tr. 2242:10 - 2244:3	
RX-123	OP-01375 Oral Pain Solutions POA II Video Script - (May 2011)	05/01/2011	EPI002129394	EPI002129403		JX-002 (Oct. 24, 2017)		Tr. 2284:13 - 2285:14	
RX-127	Opportunity Evaluation Worksheet (OEW), Target Company Johnson Matthey Pharmaceutical Materials (Feb. 25, 2011)	02/25/2011	EPI002156606	EPI002156614		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-128	Endo Opportunity Evaluation Worksheet (OEW)		EPI002156745	EPI002156755		JX-002 (Oct. 24, 2017)			
RX-129	Endo Memorandum from I. Gergel to Endo Health Solutions Board of Directors re: Opana ER Path Forward (June 26, 2013)	06/26/2013	EPI002159585	EPI002159587		JX-002 (Oct. 24, 2017)			
RX-132	Endo Opportunity Evaluation Worksheet (OEW) (June 2009)	06/01/2009	EPI002160942	EPI002160949		JX-002 (Oct. 24, 2017)			
RX-133	Impax, IPX066 Parkinson's Disease		EPI002160950	EPI002160951		JX-002 (Oct. 24, 2017)			
RX-134	Endo Spreadsheet, Imperial Valuation (June 8, 2017)	06/08/2017	EPI002161025	EPI002161066		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-137	Email from R. Cuca to D. Yocom, et al., re: APPROVAL NEEDED: OptumRx Part D Liboderm LOE and Opana ER Proposals (Apr. 29, 2013)	04/29/2013	EPI002199885	EPI002199886		JX-002 (Oct. 24, 2017)			
RX-138	Email from A. Levin to R. Cuca, et al., FW: Highly Confidential - Rule 408 Settlement Communication (May 27, 2010)	05/27/2010	EPI002199916	EPI002199917		JX-002 (Oct. 24, 2017)			
RX-139	Endo Memorandum from A. Levin to Endo Board of Directors re: 2012 Fourth Quarter, and Full Year Forecasts (Dec. 12, 2012)	12/12/2012	EPI002199971	EPI002199973		JX-002 (Oct. 24, 2017)			
RX-140	Email from D. Hudson to O. Sanchez, et al., URGENT!!! Meeting between Endo and Novartis Mfg on 1-7-12 (Jan. 7, 2012)	01/07/2012	EPI002200786	EPI002200786		JX-002 (Oct. 24, 2017)			
RX-141	Minutes of a Special Meeting of the Board of Directors of Endo Pharmaceuticals Holdings Inc. (Jan. 8, 2012)	01/08/2012	EPI002219649	EPI002219650		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-142	Minutes of a Regular Meeting of the Board of Directors of Endo Pharmaceuticals Holdings Inc. (Feb. 22, 2012)	02/22/2012	EPI002219651	EPI002219693		JX-002 (Oct. 24, 2017)			
RX-144	Email from M. Arroyo to B. Riker, et al., re: IMS Service Contact-Follow-up Summary (July 16, 2014)	07/16/2014	Impax_Opana_PartIII_0000939	Impax_Opana_PartIII_0000940		JX-002 (Oct. 24, 2017)			
RX-145	Email from T. Engle to M. Macdonald re: Oxymorphone ER teledetailing (July 3, 2014) with attachments	07/03/2014	Impax_Opana_PartIII_0000943	Impax_Opana_PartIII_0000950		JX-002 (Oct. 24, 2017)			
RX-146	Email from M. Cooper to B. Riker, et al., re: Materials for the Oxymorphone Outbound Program (June 27, 2014), with attachments	06/27/2014	Impax_Opana_PartIII_0000962	Impax_Opana_PartIII_0000970		JX-002 (Oct. 24, 2017)			
RX-147	Email from T. Engle to M. Cooper, et al., re: Existing 4 Panel Detail Aid on Oxymorphone ER (June 6, 2014), with attachments	06/06/2014	Impax_Opana_PartIII_0000971	Impax_Opana_PartIII_0000974		JX-002 (Oct. 24, 2017)			
RX-148	IMS Health Presentation, Chronic Pain Target List Kick-off Review (June 6, 2014)	06/06/2014	Impax_Opana_PartIII_0000975	Impax_Opana_PartIII_0000993		JX-002 (Oct. 24, 2017)			
RX-153	Back-Up Materials to Carole Ben-Maimon's Presentation: Impax New Product Launches (Dec. 10, 2013)	12/10/2013	Impax_Opana_PartIII_0002346	Impax_Opana_PartIII_0002380		JX-002 (Oct. 24, 2017)			
RX-156	Impax Board Presentation, 2015 Preliminary Plan (Non-GAAP) (Dec. 11, 2014)	12/11/2014	Impax_Opana_PartIII_0002723	Impax_Opana_PartIII_0002738		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-157	Impax Specialty Pharma, Board of Directors Meeting (Dec. 9, 2015)	12/09/2015	Impax_Opana_PartIII_0002758	Impax_Opana_PartIII_0002788		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-158	Impax Pharmaceuticals Update (Feb. 26, 2014)	02/26/2014	Impax_Opana_PartIII_0003397	Impax_Opana_PartIII_0003472		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-159	Impax Generic Business, Commercial Update, Board of Directors Meeting (Sept. 1, 2015)	09/01/2015	Impax_Opana_PartIII_0003519	Impax_Opana_PartIII_0003565		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-161	Impax Pharmaceuticals Board Presentation (Aug. 17, 2010)	08/17/2010	Impax_Opana_PartIII_0003803	Impax_Opana_PartIII_0003847		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-162	Impax Pharmaceuticals Board Presentation (Aug. 17, 2010)	08/17/2010	Impax_Opana_PartIII_0003854	Impax_Opana_PartIII_0003898		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-164	Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc. (Feb. 16 & 17, 2011)	02/16/2011	Impax_Opana_PartIII_0004149	Impax_Opana_PartIII_0004155		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-165	Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc. (Feb. 22-24, 2010)	02/22/2010	Impax_Opana_PartIII_0004158	Impax_Opana_PartIII_0004162		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-167	Minutes of the Meeting of the Audit Committee of the Board of Directors of Impax Laboratories, Inc. (Apr. 30, 2012)	04/30/2012	Impax_Opana_PartIII_0004177	Impax_Opana_PartIII_0004178		JX-002 (Oct. 24, 2017)			
RX-169	Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc. (Nov. 17-18, 2009)	11/17/2009	Impax_Opana_PartIII_0004192	Impax_Opana_PartIII_0004194		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-171	Email from T. Bright to J. Camargo, et al., re: June Plan (May 24, 2010), with attachments	05/24/2010	Impax_Opana_PartIII_0004886	Impax_Opana_PartIII_0004892		JX-002 (Oct. 24, 2017)			
RX-172	Email from T. Bright to C. Hildenbrand, et al., re: Forecasts from 1/09 to present (June 16, 2010), with attachments	06/16/2010	Impax_Opana_PartIII_0006050	Impax_Opana_PartIII_0006088		JX-002 (Oct. 24, 2017)			
RX-173	Email from C. Hildenbrand to J. Camargo, et al., re: OXM Launch Build (Apr. 30, 2010)	04/30/2010	Impax_Opana_PartIII_0008798	Impax_Opana_PartIII_0008798		JX-002 (Oct. 24, 2017)			
RX-174	Impax Memorandum from J. Camargo to C. Hildenbrand re: Monthly Report - February 2010 (Mar. 9, 2010)	03/09/2010	Impax_Opana_PartIII_0013798	Impax_Opana_PartIII_0013800		JX-002 (Oct. 24, 2017)			
RX-176	Email from J. Camargo to C. Mengler, et al., re: Launch Projections (June 4, 2009)	06/04/2009	Impax_Opana_PartIII_0017869	Impax_Opana_PartIII_0017869		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-178	Email from J. Camargo to M. Fitch, et al. (Oct. 12, 2011)	10/12/2011	Impax_Opana_PartIII_0021874	Impax_Opana_PartIII_0021875		JX-002 (Oct. 24, 2017)			
RX-181	Email from J. Camargo to C. Mengler, et al., re: Launch Projections (June 4, 2009)	06/04/2009	Impax_Opana_PartIII_0025094	Impax_Opana_PartIII_0025094		JX-002 (Oct. 24, 2017)		Tr. 1007:22 - 1011:23 Tr. 1037:18 - 1039:5	
RX-183	Email from D. Paquette to J. Camargo, et al., Sales & Operations (S&OP) Meeting (Dec. 22, 2009), with attachments	12/22/2009	Impax_Opana_PartIII_0026573	Impax_Opana_PartIII_0026599		JX-002 (Oct. 24, 2017)			
RX-184	Email from K. Sica to D. Paquette, et al., re: June 09 Forecast Submission (June 5, 2009), with attachments	06/05/2009	Impax_Opana_PartIII_0026901	Impax_Opana_PartIII_0026902	CX2819	JX-002 (Oct. 24, 2017)			
RX-185	Email from J. Camargo to J. Anthony, et al., re: Attached Image (Jan. 6, 2010)	01/06/2010	Impax_Opana_PartIII_0027107	Impax_Opana_PartIII_0027108		JX-002 (Oct. 24, 2017)			
RX-186	Email from J. Camargo to C. Hildenbrand, et al., re: Monthly Report (May 7, 2010), with attachments	05/07/2010	Impax_Opana_PartIII_0029196	Impax_Opana_PartIII_0029199		JX-002 (Oct. 24, 2017)		Tr. 1014:24 - 1016:10	
RX-188	Impax Memorandum from J. Camargo to C. Hildenbrand re: Monthly Report - May 2010 (June 8, 2010)	06/08/2010	Impax_Opana_PartIII_0030762	Impax_Opana_PartIII_0030765		JX-002 (Oct. 24, 2017)			
RX-190	Email from B. Reasons to B. Roche, et al., FW: attached (Apr. 30, 2013), with attachment	04/30/2013	Impax_Opana_PartIII_0037931	Impax_Opana_PartIII_0037935		JX-002 (Oct. 24, 2017)			
RX-191	Email from L. Hsu to A. Koch, et al., re: ENDP US: Endo Pharmaceuticals Holdings Inc: Opana ER Risk/Opportunity Update-BUY-United States-6pp (May 14, 2010), with attachments	05/14/2010	Impax_Opana_PartIII_0037996	Impax_Opana_PartIII_0037997		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-192	Email from M. Donohue to C. Mengler, et al., Re: Courtesy of Business Wire: -Endo, Penwest settle patent lawsuits over painkiller (June 8, 2010), with attachment	06/08/2010	Impax_Opana_PartIII_0038966	Impax_Opana_PartIII_0038966		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-193	Email from M. Donohue to B. Reasons, DRAFT-1 Reasons 3Q script (Oct. 23, 2012), with attachment	10/23/2012	Impax_Opana_PartIII_0040331	Impax_Opana_PartIII_0040331		JX-002 (Oct. 24, 2017)			
RX-196	Email from J. Camargo to T. Smolenski re: Carprofen Chewable Approval and Launch Date and Opana ER (May 28, 2009)	05/28/2009	Impax_Opana_PartIII_0049992	Impax_Opana_PartIII_0049994		JX-002 (Oct. 24, 2017)			
RX-197	Email from C. Hildenbrand to J. Camargo, et al., re: Common Goals (Feb. 3, 2009)	02/03/2009	Impax_Opana_PartIII_0051055	Impax_Opana_PartIII_0051056		JX-002 (Oct. 24, 2017)			
RX-198	Email from T. Fink to D. Ailinger, et al., re: EXTERNAL RE: Urgent Termination Agreement Needs to be Signed Before Year End (Dec. 23, 2005), with attachments	12/23/2005	Impax_Opana_PartIII_0054927	Impax_Opana_PartIII_0054933		JX-002 (Oct. 24, 2017)			
RX-199	Email from M. Nestor to S. Gupta re: IPX203 (Mar. 10, 2015), with attachments	03/10/2015	Impax_Opana_PartIII_0056962	Impax_Opana_PartIII_0056992		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-200	Email from M. Nestor to S. Gupta re: Impax/Endo Development and Co-Promotion Agreement Milestones (Sept. 22, 2014)	09/22/2014	Impax_Opana_PartIII_0057903	Impax_Opana_PartIII_0057907		JX-002 (Oct. 24, 2017)			
RX-201	Email from M. Nestor to S. Gupta re: R&D Meeting Update (Mar. 24, 2015)	03/24/2015	Impax_Opana_PartIII_0058315	Impax_Opana_PartIII_0058316		JX-002 (Oct. 24, 2017)			
RX-202	Email from A. Gaynor to S. Gupta re: 203 Restart Celebration - Please Confirm Logistics (July 13, 2015)	07/13/2015	Impax_Opana_PartIII_0058317	Impax_Opana_PartIII_0058318		JX-002 (Oct. 24, 2017)			
RX-204	Email from V. Gupta to M. Nestor re: IPX203 ER Final Formulation Dissolution (Sept. 24, 2015)	09/24/2015	Impax_Opana_PartIII_0061406	Impax_Opana_PartIII_0061406		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-205	Email from S. Gupta to F. Wilkinson, et al., Specialty RD Project Management slides & Excel file, with attachments (Nov. 11, 2012)	11/11/2012	Impax_Opana_PartIII_0061613	Impax_Opana_PartIII_0061629		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-206	Email from S. Gupta to M. Nestor re: Is 203 Project a Go? (Jan. 15, 2015)	01/15/2015	Impax_Opana_PartIII_0061632	Impax_Opana_PartIII_0061632		JX-002 (Oct. 24, 2017)		Tr. 2987:5 - 2990:14	
RX-207	Email from A. Gaynor to M. Nestor re: IPX203 CT Minutes(Jan. 10, 2015), with attachments	01/10/2015	Impax_Opana_PartIII_0062125	Impax_Opana_PartIII_0062168		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-208	IPX203 Project Update (Apr. 15, 2015)	04/15/2015	Impax_Opana_PartIII_0063064	Impax_Opana_PartIII_0063080		JX-002 (Oct. 24, 2017)		Tr. 2964:3 - 2967:7	Granted (Oct. 23, 2017)
RX-209	Email from M. Landolfi to S. Gupta, et al., re: IPX203 IND (Nov. 20, 2014), with attachments	11/20/2014	Impax_Opana_PartIII_0063401	Impax_Opana_PartIII_0063409		JX-002 (Oct. 24, 2017)			
RX-212	Email from A. Koch to L. Hsu, RE: R&D Collaboration (June 6, 2010)	06/06/2010	Impax_Opana_PartIII_0063779	Impax_Opana_PartIII_0063780	CX2697	JX-002 (Oct. 24, 2017)			
RX-217	Email from L. Hsu to C. Mengler, et al., re: Oxymorphone ER Tablets Tentatively Approved Today!! (May 13, 2010)	05/13/2010	Impax_Opana_PartIII_0069545	Impax_Opana_PartIII_0069545		JX-002 (Oct. 24, 2017)			
RX-218	Email from M. Nestor to D. Ailinger, et al., re: EXTERNAL; IPX203 (May 13, 2015)	05/13/2015	Impax_Opana_PartIII_0071701	Impax_Opana_PartIII_0071702		JX-002 (Oct. 24, 2017)		Tr. 2969:17 - 2971:21	
RX-219	Email from D. Macpherson to M. Snowden re: EXTERNAL: ENDO/IMPAX: Amendment to Development and Co-Promotional Agreement (Dec. 8, 2015)	12/08/2015	Impax_Opana_PartIII_0071911	Impax_Opana_PartIII_0071913		JX-002 (Oct. 24, 2017)			
RX-220	Email from G. Hill to J. Miller re: EXTERNAL: ENDO/IMPAX: Amendment to Development and Co-Promotional Agreement (Nov. 3, 2015)	11/03/2015	Impax_Opana_PartIII_0073230	Impax_Opana_PartIII_0073232		JX-002 (Oct. 24, 2017)			
RX-221	Email from G. Hill to B. Reasons, et al., RE:EXTERNAL:ENDO/IMPAX: Amendment to Development and Co-promotional Agreement (Oct. 29, 2015)	10/29/2015	Impax_Opana_PartIII_0073236	Impax_Opana_PartIII_0073237		JX-002 (Oct. 24, 2017)		Tr. 458:20 - 461:22 Tr. 496:16 - 497:25 Tr. 3047:24 - 3049:16	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-222	IPX203 - Review (Feb. 18, 2015)	02/18/2015	Impax_Opana_PartIII_0073375	Impax_Opana_PartIII_0073392		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-223	Email from S. Mortimer to M. Nestor re: IPX066 Partnering Process / IPX231 (May 13, 2014), with attachments	05/13/2014	Impax_Opana_PartIII_0073696	Impax_Opana_PartIII_0073706		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-224	Email from S. Gupta to F. Wilkinson, et al., re: IPX203 Brand Update_16Apr2015 (with CMC)_final.potx (Apr. 16, 2015), with attachments	04/16/2015	Impax_Opana_PartIII_0077003	Impax_Opana_PartIII_0077023		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-225	Impax Pharmaceuticals Update - DRAFT (Aug. 19, 2014)	08/19/2014	Impax_Opana_PartIII_0077025	Impax_Opana_PartIII_0077061		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-227	Minocycline ER Tabs (Solodyn): Assessment for At- Risk Launch		Impax_Opana_PartIII_0079856	Impax_Opana_PartIII_0079879		JX-002 (Oct. 24, 2017)			
RX-228	Email from C. Atwell to D. Ailinger re: IPX203 Calculation (Apr. 27, 2015), with attachments	04/27/2015	Impax_Opana_PartIII_0079934	Impax_Opana_PartIII_0079935		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-229	Oxymorphone Hydrochloride Extended-Release Tablets (Mar. 31, 2014)	03/31/2014	Impax_Opana_PartIII_0080238	Impax_Opana_PartIII_0080240		JX-002 (Oct. 24, 2017)			
RX-230	Oxymorphone Label		Impax_Opana_PartIII_0080241	Impax_Opana_PartIII_0080243		JX-002 (Oct. 24, 2017)			
RX-231	Oxymorphone Hydrochloride Extended-Release Tablets (June 2013)	06/01/2013	Impax_Opana_PartIII_0080244	Impax_Opana_PartIII_0080246		JX-002 (Oct. 24, 2017)			
RX-233	Oxymorphone Hydrochloride Extended-Release Tablets (June 2014)	06/01/2014	Impax_Opana_PartIII_0080249	Impax_Opana_PartIII_0080251		JX-002 (Oct. 24, 2017)			
RX-234	Impax Monthly Brand BD Meeting (Mar. 26, 2009)	03/26/2009	Impax_Opana_PartIII_0080630	Impax_Opana_PartIII_0080651		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-235	Impax Pharmaceuticals Update (Dec. 10, 2013)	12/10/2013	Impax_Opana_PartIII_0080655	Impax_Opana_PartIII_0080693		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-236	Email from A. Gaynor to D. Ailinger, et al., re: IPX203 Phase 3 Costing Slides (May 29, 2015), with attachments	05/29/2015	Impax_Opana_PartIII_0080915	Impax_Opana_PartIII_0080920		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-237	Email from Y. Kang to D. Ailinger, et al., re: Impax Brand Pipeline (May 29, 2015), with attachment	05/29/2015	Impax_Opana_PartIII_0080921	Impax_Opana_PartIII_0080966		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-238	Email from A. Gaynor to D. Ailinger, et al., re: IPX203 - Final PEC Slides from Joyce (July 29, 2015), with attachments	07/29/2015	Impax_Opana_PartIII_0080967	Impax_Opana_PartIII_0080991		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-240	Email from Y. Kang to M. Nestor, et al., re: IPX203 Go Alone Scenario and PD Franchise Forecast (Dec. 14, 2015), with attachments	12/14/2015	Impax_Opana_PartIII_0081126	Impax_Opana_PartIII_0081175		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-241	IPX203 Hours Spreadsheet		Impax_Opana_PartIII_0081315	Impax_Opana_PartIII_0081315		JX-002 (Oct. 24, 2017)		Tr. 2971:22 - 2972:11	Granted (Oct. 23, 2017)
RX-242	IPX203 Hours Spreadsheet		Impax_Opana_PartIII_0081316	Impax_Opana_PartIII_0081316		JX-002 (Oct. 24, 2017)			
RX-243	Impax Annual Market Summary - IPX203 for Parkinson's Disease (United States)/Base Case Scenario		Impax_Opana_PartIII_0081330	Impax_Opana_PartIII_0081330		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-244	Email from N. Modi to A. Hsu, et al. re: Extendopa 11-17-09.ppt (Nov. 17, 2009), with attachments	11/17/2009	Impax_Opana_PartIII_0081369	Impax_Opana_PartIII_0081385		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-245	Email from S. Mortimer to N. Modi re: Extendopa 11- 17-09.ppt (Nov. 17, 2009), with attachments	11/17/2009	Impax_Opana_PartIII_0081386	Impax_Opana_PartIII_0081402		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-246	Impax Presentation, Portfolio Executive Committee (PEC) Meeting (July 2, 2015)	07/02/2015	Impax_Opana_PartIII_0081403	Impax_Opana_PartIII_0081450		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-247	Email from S. Mortimer to D. Anthony, et al., re: extendopa.ppt (Nov. 24, 2009), with attachments	11/24/2009	Impax_Opana_PartIII_0081451	Impax_Opana_PartIII_0081461		JX-002 (Oct. 24, 2017)		Tr. 2951:19 - 2953:6	Granted (Oct. 23, 2017)
RX-248	Email from A. Mittur to H. Yao re: Bacterial Degradation of LD esters (June 11, 2010)	06/11/2010	Impax_Opana_PartIII_0081481	Impax_Opana_PartIII_0081481		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-249	Email from M. Soto to S. Gupta re: Trip on Sept. 6 (June 23, 2017)	06/23/2017	Impax_Opana_PartIII_0081541	Impax_Opana_PartIII_0081542		JX-002 (Oct. 24, 2017)			
RX-250	Email from L. Zhu to A. Hsu, et al., re: V1512 Discussions (Mar. 26, 2009)	03/26/2009	Impax_Opana_PartIII_0081554	Impax_Opana_PartIII_0081555		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-251	Letter from M. Flax to Hon. K. Hayden re: Endo Pharms. Inc., et al. v. Impax Labs, Inc., Civil Action No. 09-831 (KSH-PS)(D.N.J.) (May 20, 2010)	05/20/2010	Impax_Opana_PartIII_0081585	Impax_Opana_PartIII_0081585		JX-002 (Oct. 24, 2017)		Tr. 471:2 - 473:4	
RX-252	Impax Presentation, Caco-2 Permeability of LD and LD Ethyl Ester		Impax_Opana_PartIII_0081596	Impax_Opana_PartIII_0081599		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-253	IPX-203 Test Substance Spreadsheet		Impax_Opana_PartIII_0081648	Impax_Opana_PartIII_0081648		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-254	Letter from Cyprotex to A. Mittur re: Proposals for Services (Nov. 2, 2011)	11/02/2011	Impax_Opana_PartIII_0081651	Impax_Opana_PartIII_0081655		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-255	Letter from Appredica to A. Ding re: Proposal for Caco-2 Permeability (Nov. 11, 2010)	11/11/2010	Impax_Opana_PartIII_0081660	Impax_Opana_PartIII_0081669		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-256	IPX-203 Test Substance Spreadsheet		Impax_Opana_PartIII_0081670	Impax_Opana_PartIII_0081670		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-257	DRAFT Final Report, Appredica Study: Caco-2 Permeability of Test Agents		Impax_Opana_PartIII_0081671	Impax_Opana_PartIII_0081679		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-258	Email from C. Hildenbrand to J. Camargo, et al., re: June Plan (May 25, 2010)	05/25/2010	Impax_Opana_PartIII_0081683	Impax_Opana_PartIII_0081683		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-259	Email from M. Soto to S. Gupta re: Vernails Due Diligence Trip (June 23, 2017)	06/23/2017	Impax_Opana_PartIII_0081767	Impax_Opana_PartIII_0081768		JX-002 (Oct. 24, 2017)			
RX-260	Defendant IMPAX's Pre-Trial Brief, Endo Pharms. Inc. v. Impax Labs., Inc., No. 09-831 (D.N.J.) (May 26, 2010)	05/26/2010	IMPAX-OPANA00001279	IMPAX-OPANA00001322		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-261	Plaintiffs' Trial Brief, Endo Pharms. Inc. v. Impax Labs., Inc., No. 09-831 (D.N.J.) (May 26, 2010)	05/26/2010	IMPAX-OPANA00001324	IMPAX-OPANA00001360		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-262	Email from T. Hassi to D. Feinstein, et al., re: Impax FTC File No. 141-0004 (Aug. 17, 2015), with attachments	08/17/2015	IMPAX-OPANA000033953	IMPAX-OPANA000033958		JX-002 (Oct. 24, 2017)			
RX-263	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Sept. 24, 2014)	09/24/2014	IMPAX-OPANA000034635	IMPAX-OPANA000034635		JX-002 (Oct. 24, 2017)		Tr. 1857:7 - 1859:8	
RX-264	Impax Annual Report 2013		IMPAX-OPANA000034910	IMPAX-OPANA000035066		JX-002 (Oct. 24, 2017)			
RX-266	Spreadsheet, NPA Ad Hoc		IMPAX-OPANA-CID00001392	IMPAX-OPANA-CID00001392		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-268	Email from A. Koch to A. Levin, et al. (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00001466	IMPAX-OPANA-CID00001470		JX-002 (Oct. 24, 2017)			
RX-270	Email from M. Nestor to R. Cobuzzi, et al., Re: R&D Contact? (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00001600	IMPAX-OPANA-CID00001600		JX-002 (Oct. 24, 2017)			
RX-271	Email from R. Cobuzzi to M. Nestor, et al., re: Information Requested (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00001601	IMPAX-OPANA-CID00001602		JX-002 (Oct. 24, 2017)			
RX-272	Email from D. Paterson to R. Cobuzzi, et al., re: IPX066 (May 22, 2010), with attachment	05/22/2010	IMPAX-OPANA-CID00001603	IMPAX-OPANA-CID00001610		JX-002 (Oct. 24, 2017)		Tr. 1157:11 - 1158:3	

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-278	Email from T. Engle to J. Camargo, et al., re: Launch Planning Input (May 18, 2010), with attachments	05/18/2010	IMPAX-OPANA-CID00001732	IMPAX-OPANA-CID00001737		JX-002 (Oct. 24, 2017)			
RX-282	Email from M. Nestor to R. Cobuzzi, et al., re: Information Requested (June 4, 2010), with attachments	06/04/2010	IMPAX-OPANA-CID00001823	IMPAX-OPANA-CID00001878		JX-002 (Oct. 24, 2017)		Tr. 2598:18 - 2601:4	Granted (Oct. 23, 2017)
RX-283	Email from C. Mengler to R. Cobuzzi, et al., re: IPX066 (May 19, 2010)	05/19/2010	IMPAX-OPANA-CID00001902	IMPAX-OPANA-CID00001902		JX-002 (Oct. 24, 2017)			
RX-285	Email from C. Mengler to A. Koch, et al., re: Follow- Up to Endo Call (Nov. 3, 2009)	11/03/2009	IMPAX-OPANA-CID00002119	IMPAX-OPANA-CID00002119		JX-002 (Oct. 24, 2017)			
RX-288	Email from J. Camargo to T. Smolenski, et al., re: Oxymorphone API (Sept. 12, 2011)	09/12/2011	IMPAX-OPANA-CID00003148	IMPAX-OPANA-CID00003149		JX-002 (Oct. 24, 2017)			
RX-289	Email from T. Engle to G. Skalski, et al., re: Oxymorphone Managed Care (Feb. 15, 2012)	02/15/2012	IMPAX-OPANA-CID00003151	IMPAX-OPANA-CID00003151		JX-002 (Oct. 24, 2017)			
RX-290	Email from J. Camargo to C. Hildenbrand re: Monthly Report (June 11, 2010), with attachments	06/11/2010	IMPAX-OPANA-CID00003159	IMPAX-OPANA-CID00003161		JX-002 (Oct. 24, 2017)			
RX-291	Email from J. Camargo to C. Hildenbrand re: Monthly Report (June 8, 2010), with attachments	06/08/2010	IMPAX-OPANA-CID00003162	IMPAX-OPANA-CID00003164		JX-002 (Oct. 24, 2017)			
RX-292	Email from T. Engle to D. Arnold re: Pls email Derek initial Strat [SIC] Plan (Feb. 17, 2012)	02/17/2012	IMPAX-OPANA-CID00003198	IMPAX-OPANA-CID00003200		JX-002 (Oct. 24, 2017)			
RX-294	Email from T. Engle to HTraveling@aol.com, et al., RE: PROPOSAL - RJH GROUP INC - PLEASE REVIEW, with attachments (Nov. 5, 2012)	11/05/2012	IMPAX-OPANA-CID00003601	IMPAX-OPANA-CID00003608		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-295	Email from T. Smolenski to M. Shaw, et al., re: Risk Map Proposal for Oxymorphone HCI ER Tablets (Mar. 7, 2011), with attachments	03/07/2011	IMPAX-OPANA-CID00003620	IMPAX-OPANA-CID00003636		JX-002 (Oct. 24, 2017)			
RX-296	Email from L. Zhu to A. Baichwal re: Interested in Partnership Opportunities (Apr. 2, 2010)	04/02/2010	IMPAX-OPANA-CID00003826	IMPAX-OPANA-CID00003827		JX-002 (Oct. 24, 2017)			
RX-297	Email from A. Koch to L. Hsu re: Bank Meetings and Debt Financing - Comments and Questions (May 10, 2010)	05/10/2010	IMPAX-OPANA-CID00003857	IMPAX-OPANA-CID00003859		JX-002 (Oct. 24, 2017)			
RX-298	Email from L. Hsu to A. Koch re: Bank Meetings and Debt Financing - Comments and Questions (May 10, 2010)	05/10/2010	IMPAX-OPANA-CID00003864	IMPAX-OPANA-CID00003866		JX-002 (Oct. 24, 2017)			
RX-299	Email from M. Shaw to T. Smolenski re: Ox-E-More- fone (Sept. 12, 2011)	09/12/2011	IMPAX-OPANA-CID00003875	IMPAX-OPANA-CID00003876		JX-002 (Oct. 24, 2017)			
RX-300	Email from S. Mortimer to T. Engle, et al., re: Opioids (May 14, 2013)	05/14/2013	IMPAX-OPANA-CID00004173	IMPAX-OPANA-CID00004176		JX-002 (Oct. 24, 2017)			
RX-301	Email from K. Sica to T. Engle re: OXY TRACKING SHEET UPDATE 3 11 2013 (Mar. 11, 2013), with attachments	03/11/2013	IMPAX-OPANA-CID00004338	IMPAX-OPANA-CID00004339		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-302	Email from T. Engle to T. Burroughs, RE: Signed Training Document (Jan. 17, 2013), with attachment	01/17/2013	IMPAX-OPANA-CID00004347	IMPAX-OPANA-CID00004347		JX-002 (Oct. 24, 2017)			
RX-303	Email from D. Richards to D. Frankel, et al., re: IMPAX Q313 Universe Lists (June 10, 2013), with attachments	06/10/2013	IMPAX-OPANA-CID00004653	IMPAX-OPANA-CID00004658		JX-002 (Oct. 24, 2017)			
RX-304	Email from M. Nestor to T. Engle re: Inventory Report for the Week Ending May 10, 2013 (May 13, 2013)	05/13/2013	IMPAX-OPANA-CID00004698	IMPAX-OPANA-CID00004698		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-305	Email from S. Fatholahi to R. Strafeldas, et al., re: Xponent Data (May 30, 2013)	05/30/2013	IMPAX-OPANA-CID00004699	IMPAX-OPANA-CID00004699		JX-002 (Oct. 24, 2017)			
RX-306	Email from C. Ben-Maimon to T. Engle re: IMS Proposal - Time Sensitive (May 31, 2013)	05/31/2013	IMPAX-OPANA-CID00004745	IMPAX-OPANA-CID00004745		JX-002 (Oct. 24, 2017)			
RX-307	Email from Y. Kang to S. Fatholahi, et al., re: Opioids (May 13, 2013), with attachments	05/13/2013	IMPAX-OPANA-CID00004973	IMPAX-OPANA-CID00004975		JX-002 (Oct. 24, 2017)			
RX-310	Email from A. Ford to S. Gupta re: EXTERNAL RE: Impax/Endo Development and Co-Promotion Agreement Milestones (Oct. 30, 2013)	10/30/2013	IMPAX-OPANA-CID00005540	IMPAX-OPANA-CID00005541		JX-002 (Oct. 24, 2017)			
RX-312	Email from T. Rayski to H. Nguyen, et al., re: Draft Impax/Endo Penwest Settlement and License Agreement (June 7, 2010), with attachments	06/07/2010	IMPAX-OPANA-CID00005685	IMPAX-OPANA-CID00005713		JX-002 (Oct. 24, 2017)			
RX-316	Email from M. Snowden to G. Donatiello re: Message (May 17, 2010)	05/17/2010	IMPAX-OPANA-CID00005934	IMPAX-OPANA-CID00005935		JX-002 (Oct. 24, 2017)			
RX-318	Email from C. Mengler to A. Levin, et al., re: Highly Confidential - Rule 408 Settlement Communication (May 27, 2010)	05/27/2010	IMPAX-OPANA-CID00005941	IMPAX-OPANA-CID00005942		JX-002 (Oct. 24, 2017)		Tr. 367:10 - 370:4 Tr. 430:22 - 432:15	
RX-319	Email from C. Mengler to A. Levin, et al. re: Meeting Today in Princeton (June 1, 2010)	06/01/2010	IMPAX-OPANA-CID00005960	IMPAX-OPANA-CID00005961		JX-002 (Oct. 24, 2017)			
RX-320	Meeting Invite re: Settlement and License Agreement Discussion (June 5, 2010)	06/05/2010	IMPAX-OPANA-CID00005974	IMPAX-OPANA-CID00005974		JX-002 (Oct. 24, 2017)			
RX-321	Email from A. Koch to A. Levin, et al., re: Cost of Goods (June 7, 2010), with attachments	06/07/2010	IMPAX-OPANA-CID00005996	IMPAX-OPANA-CID00005998		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-322	Email from T. Rayski to H. Nguyen, et al., re: Draft Impax/Endo Penwest Settlement and License Agreement (June 7, 2010), with attachments	06/07/2010	IMPAX-OPANA-CID00006036	IMPAX-OPANA-CID00006037		JX-002 (Oct. 24, 2017)			
RX-323	Email from M. Grigsby to T. Smolenski, et al., re: Tentative Oxy ER Approval (May 17, 2010)	05/17/2010	IMPAX-OPANA-CID00006042	IMPAX-OPANA-CID00006042		JX-002 (Oct. 24, 2017)		Tr. 1778:10 - 1782:4	
RX-324	Email from T. Smolenski to C. Mengler, et al., re: Tentative Oxy ER Approval (May 19, 2010)	05/19/2010	IMPAX-OPANA-CID00006043	IMPAX-OPANA-CID00006043		JX-002 (Oct. 24, 2017)			
RX-325	Meeting Invite re: Co-Promotion Agreement Discussion (June 5, 2010)	06/05/2010	IMPAX-OPANA-CID00006136	IMPAX-OPANA-CID00006136		JX-002 (Oct. 24, 2017)			
RX-327	Email from M. Snowden to G. Donatiello, et al., re: Steering Committee (Dec. 20, 2010)	12/20/2010	IMPAX-OPANA-CID00006402	IMPAX-OPANA-CID00006403	CX2845	JX-002 (Oct. 24, 2017)			
RX-328	License, Development and Commercialization Agreement (Dec. 15, 2010)	12/15/2010	IMPAX-OPANA-CID00006530	IMPAX-OPANA-CID00006563		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-332	DRAFT Term Sheet (May 26, 2010)	05/26/2010	IMPAX-OPANA-CID00006720	IMPAX-OPANA-CID00006723		JX-002 (Oct. 24, 2017)			
RX-333	DRAFT - Non-Binding Term Sheet (May 26, 2010)	05/26/2010	IMPAX-OPANA-CID00006724	IMPAX-OPANA-CID00006729		JX-002 (Oct. 24, 2017)			
RX-335	Dechert DRAFT of Settlement and License Agreement (June 6, 2010)	06/06/2010	IMPAX-OPANA-CID00006734	IMPAX-OPANA-CID00006781		JX-002 (Oct. 24, 2017)			
RX-336	Email from H. Nguyen to G. Donatiello, et al., re: Draft Impax/Endo/Penwest Settlement and License Agreement (June 7, 2010), with attachments	06/07/2010	IMPAX-OPANA-CID00006786	IMPAX-OPANA-CID00006852		JX-002 (Oct. 24, 2017)			
RX-337	Email from A. Freeman-Gleason to J. Watkins, et al., re: Co-Promote	06/07/2010	IMPAX-OPANA-CID00006963	IMPAX-OPANA-CID00007030		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay ¹	Discussed	In Camera Status
	Revisions (June 7, 2010), with attachments								
RX-340	Email from T. Smolenski to C. Hildenbrand, et al., re: Oxycodone and Oxymorphone (Oct. 21, 2010), with attachments	10/21/2010	IMPAX-OPANA-CID00007211	IMPAX-OPANA-CID00007216		JX-002 (Oct. 24, 2017)			
RX-342	Email from T. Engle to G. Skalski, et al., Approved talking points on Endo's CP on Oxymorphone ER, with attachments, (May 22, 2013)	05/22/2013	IMPAX-OPANA-CID00007572	IMPAX-OPANA-CID00007590		JX-002 (Oct. 24, 2017)			
RX-346	Email from A. Koch to C. Hildenbrand, et al., re: Impax Inventory Carrying Value - June 30, 2010- OXM (June 24, 2010)	06/24/2010	IMPAX-OPANA-CID00008080	IMPAX-OPANA-CID00008082		JX-002 (Oct. 24, 2017)			
RX-347	Email from C. Ben-Maimon to S. Ostrander re: EXECUTIVE SUMMARY - OXYMORPHONE SURVEY (Dec. 11, 2012), with attachments	12/11/2012	IMPAX-OPANA-CID00008083	IMPAX-OPANA-CID00008100		JX-002 (Oct. 24, 2017)			
RX-348	Email from C. Ben-Maimon to L. Hsu re: EXECUTIVE SUMMARY - OXYMORPHONE SURVEY (Dec. 11, 2012), with attachments	12/11/2012	IMPAX-OPANA-CID00009210	IMPAX-OPANA-CID00009227		JX-002 (Oct. 24, 2017)			
RX-350	Email from T. Engle to G. Skalski re: Managed Care Advisory Board-Chicago (Apr. 16, 2012), with attachments	04/16/2012	IMPAX-OPANA-CID00010848	IMPAX-OPANA-CID00010938		JX-002 (Oct. 24, 2017)			
RX-351	Email from T. Smolenski to K. Sica, et al., re: Oxymorphone 7.5 and 15mg (Mar. 4, 2011)	03/04/2011	IMPAX-OPANA-CID00011030	IMPAX-OPANA-CID00011030		JX-002 (Oct. 24, 2017)			
RX-352	Email from T. Smolenski to M. Shaw, et al., re: Oxymorphone 7.5 and 15mg (Mar. 14, 2011)	03/14/2011	IMPAX-OPANA-CID00011070	IMPAX-OPANA-CID00011070		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-353	Email from S. Fatholahi to M. Nestor re: Actavis' Generic Opana ER Receives FDA Approval (Aug. 21, 2013), with attachments	08/21/2013	IMPAX-OPANA-CID00011576	IMPAX-OPANA-CID00011582		JX-002 (Oct. 24, 2017)			
RX-354	Email from S. Gupta to J. Miller, et al., RE: Update Requested=> Impax-Endo Agreement, with attachment, (July 2, 2012)	07/02/2012	IMPAX-OPANA-CID00011718	IMPAX-OPANA-CID00011725		JX-002 (Oct. 24, 2017)			
RX-359	Email from G. Donatiello to M. Snowden re: Email Address (Oct. 16, 2009)	10/16/2009	IMPAX-OPANA-CID00011926	IMPAX-OPANA-CID00011934		JX-002 (Oct. 24, 2017)			
RX-364	Settlement and License Agreement (June 7, 2010)	06/07/2010	IMPAX-OPANA-CID00012073	IMPAX-OPANA-CID00012098	CX2626	JX-002 (Oct. 24, 2017)		Tr. 398:17 - 398:21 Tr. 473:23 - 477:2 Tr. 632:4 - 641:5 Tr. 669:18 - 676:25 Tr. 1737:19 - 1741:23 Tr. 1748:8 - 1751:7 Tr. 1791:19 - 1796:2 Tr. 2716:19 - 2724:4	
RX-365	Development and Co-Promotion Agreement between Endo Pharmaceuticals Inc. and Impax Laboratories, Inc. (June 7, 2010)	06/07/2010	IMPAX-OPANA-CID00012099	IMPAX-OPANA-CID00012132		JX-002 (Oct. 24, 2017)		Tr. 397:14 - 398:16 Tr. 398:22 - 403:2 Tr. 406:17 - 408:25 Tr. 2602:16 - 2603:16 Tr. 3035:22 - 3037:10 Tr. 3045:12 - 3047:23	
RX-366	Email from J. De Los Reyes to A. Koch, et al., re: Approval Date Expectations (June 4, 2008), with attachments	06/04/2008	IMPAX-OPANA-CID00012325	IMPAX-OPANA-CID00012326		JX-002 (Oct. 24, 2017)			
RX-367	Email from J. De Los Reyes to T. Smolenski re: Generic New Product Launch Projection 052108.xls (May 21, 2008)	05/21/2008	IMPAX-OPANA-CID00012337	IMPAX-OPANA-CID00012338		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-371	Email from B. Smith to M. Nestor, RE: Slide format, with attachment (July 5, 2013)	07/05/2013	IMPAX-OPANA-CID00016117	IMPAX-OPANA-CID00016136		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-372	Email from J. Hsu to L. His, May 2013 Board Meeting final presentations, with attachments, (May 17, 2013)	05/17/2013	IMPAX-OPANA-CID00016868	IMPAX-OPANA-CID00016901		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-373	Email from C. Mengler to L. Bisbing, et al., re: Mengler Board Materials (May 17, 2010), with attachments	05/17/2010	IMPAX-OPANA-CID00018058	IMPAX-OPANA-CID00018081		JX-002 (Oct. 24, 2017)			
RX-375	Email from J. Hsu to A. Koch, et al., re: BOD Monthly Update - Feb. 10 - CONFIDENTIAL (Apr. 2, 2010), with attachments	04/02/2010	IMPAX-OPANA-CID00018174	IMPAX-OPANA-CID00018193		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-376	Email from M. Nestor to A. Koch, et al., re: Info Requested by Endo on Successor to IPX-066 (June 4, 2010), with attachments	06/04/2010	IMPAX-OPANA-CID00018251	IMPAX-OPANA-CID00018300	CX2963	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-377	Impax Presentation, IPX-203 (June 3, 2010)	06/03/2010	IMPAX-OPANA-CID00018252	IMPAX-OPANA-CID00018295	CX2963; CX2780	JX-002 (Oct. 24, 2017)		Tr. 1195:2 - 1196:10 Tr. 1196:21 - 1197:7 Tr. 2527:20 - 2538:2	Granted (Oct. 23, 2017)
RX-378	Impax Presentation, IPX066: Commercial Opportunity for Parkinson's Disease (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00018296	IMPAX-OPANA-CID00018300	CX2931; CX2780	JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-379	Email from T. Smolenski to T. Engle, et al., re: Oxymorphone (Jan. 7, 2011)	01/07/2011	IMPAX-OPANA-CID00018344	IMPAX-OPANA-CID00018345		JX-002 (Oct. 24, 2017)			
RX-380	Email from M. Donahue to L. Hsu, et al., re: Endo Opana Earnings Call Comments (May 1, 2012)	05/01/2012	IMPAX-OPANA-CID00018811	IMPAX-OPANA-CID00018814		JX-002 (Oct. 24, 2017)			
RX-381	Email from C. Ben-Maimon to T. Engle re: Endo Opana Earnings Call Comments (May 1, 2012)	05/01/2012	IMPAX-OPANA-CID00018997	IMPAX-OPANA-CID00019000		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-383	Email from L. Hsu to C. Ben-Maimon, Re: Endo Pharma. (ENDP, BUY): Another Hurdle for Generic Opanas - No RLD, (June 27, 2012)	06/27/2012	IMPAX-OPANA-CID00019187	IMPAX-OPANA-CID00019189		JX-002 (Oct. 24, 2017)			
RX-384	Email from C. Ben-Maimon to T. Engle re: Board Meeting Presentation (Apr. 23, 2013)	04/23/2013	IMPAX-OPANA-CID00019244	IMPAX-OPANA-CID00019244		JX-002 (Oct. 24, 2017)			
RX-385	Email from T. Engle to S. Fatholahi re: Oxymorphone ER (May 13, 2013)	05/13/2013	IMPAX-OPANA-CID00019266	IMPAX-OPANA-CID00019266		JX-002 (Oct. 24, 2017)			
RX-386	Email from C. Mengler to L. Hsu re: Today's Meeting (June 1, 2010)	06/01/2010	IMPAX-OPANA-CID00019433	IMPAX-OPANA-CID00019433		JX-002 (Oct. 24, 2017)			
RX-387	Email from M. Nestor to C. Mengler, et al., re: Today's Meeting (June 1, 2010)	06/01/2010	IMPAX-OPANA-CID00019440	IMPAX-OPANA-CID00019441		JX-002 (Oct. 24, 2017)		Tr. 2945:11 - 2949:1	
RX-388	Email from T. Smolenski to C. Mengler re: Today's Meeting (June 2, 2010)	06/02/2010	IMPAX-OPANA-CID00019446	IMPAX-OPANA-CID00019447		JX-002 (Oct. 24, 2017)			
RX-393	Email from D. Paterson to A. Koch, et al., re: For 2:00pm (Apr. 21, 2009), with attachments	04/21/2009	IMPAX-OPANA-CID00020159	IMPAX-OPANA-CID00020180		JX-002 (Oct. 24, 2017)		Tr. 317:6 - 319:2	Granted (Oct. 23, 2017)
RX-394	Kenetwork Communications, Inc., Invoice to Impax (May 13, 2013)	05/13/2013	IMPAX-OPANA-CID00020424	IMPAX-OPANA-CID00020425		JX-002 (Oct. 24, 2017)			
RX-398	Email from T. Smolenski to C. Mengler re: Research Note - ENDO First Settlement for Generic Opana ER (Feb. 23, 2009)	02/23/2009	IMPAX-OPANA-CID00020836	IMPAX-OPANA-CID00020837		JX-002 (Oct. 24, 2017)		Tr. 1939:2 - 1940:14	
RX-399	Email from L. Hsu to T. Smolenski, et al., re: Research Note - ENDO Fist Settlement for Generic Opana ER (Feb. 23, 2009)	02/23/2009	IMPAX-OPANA-CID00020881	IMPAX-OPANA-CID00020882		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-400	Email from C. Mengler to M. Donahue, et al., re: Courtesy of Business Wire: Endo Penwest Settle Patent Lawsuits Over Painkiller (June 8, 2010)	06/08/2010	IMPAX-OPANA-CID00021060	IMPAX-OPANA-CID00021061		JX-002 (Oct. 24, 2017)			
RX-401	Email from M. Shaw to T. Smolenski, et al., re: (BN) ENDO TO DISCONTINUE 7.5MG, 15 MG STRENGTHS OF OPANA ER, FDA SAYS (Mar. 1, 2011)	03/01/2011	IMPAX-OPANA-CID00021123	IMPAX-OPANA-CID00021125		JX-002 (Oct. 24, 2017)			
RX-402	Email from T. Smolenski to K. Sica, FE: Draft Impax/Endo/Penwest Settlement and License Agreement (July 6, 2010) with attachments	07/06/2010	IMPAX-OPANA-CID00021237	IMPAX-OPANA-CID00021265		JX-002 (Oct. 24, 2017)			
RX-403	Email from T. Smolenski to A. Fox, et al., re: Meeting Minutes, NPC September 1, 2010 (Sept. 1, 2010), with attachments	09/01/2010	IMPAX-OPANA-CID00021394	IMPAX-OPANA-CID00021405		JX-002 (Oct. 24, 2017)			
RX-405	Email from L. Hsu to A. Koch re: R&D Collaboration (June 6, 2010)	06/06/2010	IMPAX-OPANA-CID00021840	IMPAX-OPANA-CID00021842		JX-002 (Oct. 24, 2017)			
RX-406	Email from T. Smolenski to C. Mengler (June 4, 2010), with attachments	06/04/2010	IMPAX-OPANA-CID00022100	IMPAX-OPANA-CID00022122		JX-002 (Oct. 24, 2017)			
RX-410	Email from M. Donahue to C. Ben-Maimon, et al., re: Endo Loses in USDC in DC (Jan. 2, 2013)	01/02/2013	IMPAX-OPANA-CID00022307	IMPAX-OPANA-CID00022311		JX-002 (Oct. 24, 2017)			
RX-411	Email from M. Snowden to L. Hsu, et al., re: Highly Confidential - Rule 408 Settlement Communication (May 26, 2010)	05/26/2010	IMPAX-OPANA-CID00023787	IMPAX-OPANA-CID00023788		JX-002 (Oct. 24, 2017)			
RX-412	Email from M. Snowden to C. Mengler, et al., re: Today's Meeting (June 1, 2010)	06/01/2010	IMPAX-OPANA-CID00023799	IMPAX-OPANA-CID00023800		JX-002 (Oct. 24, 2017)			
RX-413	Email from C. Mengler to M. Snowden (June 2, 2010)	06/02/2010	IMPAX-OPANA-CID00023814	IMPAX-OPANA-CID00023815		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-414	Spreadsheet, NSP & NPA Ad Hoc		IMPAX-OPANA-CID00023836	IMPAX-OPANA-CID00023836		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-415	Email from T. Engle to K. Hertzell, FW: Draft Oxymorphone email blast w brief summary R2.docx, with attachment, (Jan. 31, 2013)	01/31/2013	IMPAX-OPANA-CID00023839	IMPAX-OPANA-CID00023844		JX-002 (Oct. 24, 2017)			
RX-416	Email from T. Engle to N. Gomez, et al., RE: final banner for Oxy, with attachment (Mar. 25, 2013)	03/25/2013	IMPAX-OPANA-CID00023845	IMPAX-OPANA-CID00023853		JX-002 (Oct. 24, 2017)			
RX-417	Cowen and Company, Quick Take, Endo Pharmaceuticals - Neutral (May 14, 2010)	05/14/2010	IMPAX-OPANA-CID00023859	IMPAX-OPANA-CID00023864		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-418	Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review (June 29, 2010)	06/29/2010	IMPAX-OPANA-CID00023865	IMPAX-OPANA-CID00023900		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-419	The Buckingham Research Group, Equity Research, Endo Pharmaceuticals Holdings (ENDP) (June 8, 2010)	06/08/2010	IMPAX-OPANA-CID00023901	IMPAX-OPANA-CID00023905		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-420	RBC Capital Markets, Company Update Comment, Endo Pharmaceuticals Holdings (Dec. 3, 2009)	12/03/2009	IMPAX-OPANA-CID00023906	IMPAX-OPANA-CID00023911		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-421	Wells Fargo, Securities, Equity Research, Endo Pharmaceuticals Holdings Inc. (May 5, 2010)	05/05/2010	IMPAX-OPANA-CID00023912	IMPAX-OPANA-CID00023917		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-422	PiperJaffray, Company Note, Endo Pharmaceuticals, Neutral (June 14, 2010)	06/14/2010	IMPAX-OPANA-CID00023918	IMPAX-OPANA-CID00023925		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-423	Barclays Capital, Equity Research, Endo Pharmaceuticals Holdings (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00023926	IMPAX-OPANA-CID00023926		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-424	Cowen and Company, Quick Take, Endo Pharmaceuticals - Neutral (2) (June 8, 2010)	01/02/1900	IMPAX-OPANA-CID00023933	IMPAX-OPANA-CID00023938		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-425	RBC Capital Markets, Pharmaceuticals: Analyzing Litigation Success Rates (Jan. 15, 2010)	01/15/2010	IMPAX-OPANA-CID00023939	IMPAX-OPANA-CID00023962		JX-002 (Oct. 24, 2017)	Non-hearsay	Tr. 2827:11 - 2831:2 Tr. 2908:14 - 2909:8	
RX-426	J.P. Morgan, Endo Pharmaceuticals, Diversifying Beyond Pharma with HelthTronics Acquisition - ALERT (May 6, 2010)	05/06/2010	IMPAX-OPANA-CID00023963	IMPAX-OPANA-CID00023968		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-427	The Buckingham Research Group, Equity Research, Endo Pharmaceuticals Holdings (ENDP) (June 16, 2010)	06/16/2010	IMPAX-OPANA-CID00023969	IMPAX-OPANA-CID00023973		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-428	Collins Stewart, Specialty Pharma, Generic Opana ER Settlement Is Positive for IPXL and ENDP (June 8, 2010)	06/08/2010	IMPAX-OPANA-CID00023974	IMPAX-OPANA-CID00023977		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-429	Gabelli & Company, Inc. Morning Meeting Notes, ENDO PHARMACEUT HLDGS INC (Feb. 23, 2010)	02/23/2010	IMPAX-OPANA-CID00023978	IMPAX-OPANA-CID00023979		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-430	New Constructs, Company Snapshot, Endo Pharmaceuticals Holdings Inc (ENDP) (June 5, 2010)	06/05/2010	IMPAX-OPANA-CID00023988	IMPAX-OPANA-CID00024006		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-431	Wells Fargo, Securities, Equity Research, Endo Pharmaceuticals Holdings Inc. (June 8, 2010)	06/08/2010	IMPAX-OPANA-CID00024007	IMPAX-OPANA-CID00024012		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-432	UBS Investment Research, Endo Pharmaceuticals Holdings (Apr. 20, 2010)	04/20/2010	IMPAX-OPANA-CID00024013	IMPAX-OPANA-CID00024024		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-433	PiperJaffray, Company Note, Endo Pharmaceuticals, Neutral (May 6, 2010)	05/06/2010	IMPAX-OPANA-CID00024025	IMPAX-OPANA-CID00024028		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-434	Duncan-Williams, Endo Pharmaceuticals Holdings, Inc. (June 23, 2010)	06/23/2010	IMPAX-OPANA-CID00024029	IMPAX-OPANA-CID00024057		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-435	The Buckingham Research Group, Equity Research, Endo Pharmaceuticals Holdings (ENDP) (June 7, 2010)	06/07/2010	IMPAX-OPANA-CID00024058	IMPAX-OPANA-CID00024063		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-436	Oppenheimer, Equity Research, Company Update, Endo Pharmaceuticals (May 5, 2010)	05/05/2010	IMPAX-OPANA-CID00024064	IMPAX-OPANA-CID00024068		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-437	Collins Stewart, Endo Pharmaceuticals (June 1, 2010)	06/01/2010	IMPAX-OPANA-CID00024069	IMPAX-OPANA-CID00024071		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-438	PriceTarget Research, Endo Pharmaceuticals Hldgs (June 20, 2010)	06/20/2010	IMPAX-OPANA-CID00024072	IMPAX-OPANA-CID00024078		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-439	PriceTarget Research, Endo Pharmaceuticals Hldgs (June 6, 2010)	06/06/2010	IMPAX-OPANA-CID00024079	IMPAX-OPANA-CID00024079		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-440	J.P. Morgan, Endo Pharmaceuticals, Opana ER Settlement Clearly Positive; Adding HealthTronics to Estimates (June 8, 2010)	06/08/2010	IMPAX-OPANA-CID00024086	IMPAX-OPANA-CID00024093		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-441	Law360 article, Endo, Penwest Reach Opana License Deal with Barr (Apr. 13, 2010)	04/13/2010	IMPAX-OPANA-CID00024125	IMPAX-OPANA-CID00024126		JX-002 (Oct. 24, 2017)			
RX-442	Law360 article, Endo, Watson Settle Litigation Over Opana ER Generic (Oct. 7, 2010)	10/07/2010	IMPAX-OPANA-CID00024580	IMPAX-OPANA-CID00024581		JX-002 (Oct. 24, 2017)			
RX-443	Law360 article, Endo Sues Sandoz Over ANDA For Generic Opana (Aug. 24, 2008)	08/24/2008	IMPAX-OPANA-CID00024585	IMPAX-OPANA-CID00024586		JX-002 (Oct. 24, 2017)			
RX-444	Purdue Presentation, OxyContin® Tablets 2009 Marketing Plan	01/01/2009	Purdue Pharma 02_000095	Purdue Pharma 02_000127		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-445	2010 OxPurdue Presentation, yContin® Tablets Budget Presentation (Nov. 2009)	11/01/2009	Purdue Pharma 02_000128	Purdue Pharma 02_000157		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-446	Purdue Presentation, 2011 OxyContin® Tablets Budget Submission (Nov. 2010)	11/01/2010	Purdue Pharma 02_000158	Purdue Pharma 02_000241		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-447	Purdue Presentation, 2012 Budget Presentations Marketing Overview (2012)	01/01/2012	Purdue Pharma 02_000242	Purdue Pharma 02_000319		JX-002 (Oct. 24, 2017)		Tr. 2286:23 - 2288:23	Granted (Oct. 20, 2017)
RX-448	Purdue Presentation, Sales & Marketing, Opiod Market Overview		Purdue Pharma 02_000320	Purdue Pharma 02_000366		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-449	2013 OxyContin® (oxycodone HCL controlled- release) Tablets Annual Marketing Plan (Oct. 6, 2013)	10/06/2013	Purdue Pharma 02_000367	Purdue Pharma 02_000400		JX-002 (Oct. 24, 2017)		Tr. 2265:11 - 2267:4	Granted (Oct. 20, 2017)
RX-450	Email from T. Smolenski to C. Mengler, et al., re: This Weekend (June 4, 2010)	06/04/2010	IMPAX-OPANA-CID00021968	IMPAX-OPANA-CID00021969		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-451	Complaint, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-832 (D. Del.) (Jan. 25, 2008), with exhibits	01/25/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-452	Complaint Ex. A, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-832 (D. Del.) (Jan. 25, 2008)	01/25/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-453	Complaint Ex. B, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-832 (D. Del.) (Jan. 25, 2008)	01/25/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-454	Answer, Affirmative Defenses, and Counterclaims of Defendant Impax Labs., Inc., Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-832 (D. Del.) (Feb. 19, 2008)	02/19/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-455	Plaintiffs' Reply to Defendant's Counterclaims, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-832 (D. Del.) (Mar. 13, 2008)	03/13/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-456	Complaint for Patent Infringement, Endo Pharms. Inc. v. Actavis South Atlantic LLC, No. 2:08-cv-1563 (D.N.J.) (Mar. 28, 2008)	03/28/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-457	Complaint, Endo Pharms. Inc. v. Sandoz Inc., No. 2:09-cv-836 (D. Del.) (Aug. 22, 2008)	08/22/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-458	Complaint, Endo Pharms. Inc. v. Barr Labs., Inc., No. 2:09-cv-838 (D. Del.) (Oct. 20, 2008)	10/20/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-459	Complaint, Endo Pharms. Inc. v. Sandoz Inc., No. 2:09-cv-839 (D. Del.) (Dec. 30, 2008)	12/30/2008	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-460	Stipulation of Dismissal and Order, Endo Pharms. Inc. v. Actavis South Atlantic LLC, No. 2:08-cv-1563 (D.N.J.) (Feb. 26, 2009)	02/26/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-461	Prescribing Patterns of Preferred or Formulary Medications		N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-462	Joint Claim Construction and Prehearing Statement Pursuant to Local Patent Rule 4.3, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (June 16, 2009)	06/16/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-463	Complaint, Endo Pharms. Inc. v. Barr Labs., Inc., No. 2:09-cv-3224 (D.N.J.) (July 2, 2009)	07/02/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-464	Defendants' Opening Claim Construction Brief, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (July 22, 2009)	07/22/2009	N/A	N/A	CX2763	JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-465	Plaintiffs' Opening Markman Brief, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (July 22, 2009)	07/22/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-466	Impax Labs, Paragraph IV Patent Certification (Oct. 27, 2009)	10/27/2009	N/A	N/A	CX3449	JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-467	Expert Report of Stephen Levine, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Dec. 9, 2009)	12/09/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-468	Expert Report of Edmund J. Elder, Jr., Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Dec. 9, 2009)	12/09/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-469	Expert Report of Anthony Lowman, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Dec. 10, 2009)	12/10/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-470	Expert Report of Danny D. Shen, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Dec. 10, 2009)	12/10/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-471	Expert Report of Arthur H. Kibbe, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Dec. 10, 2009)	12/10/2009	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-472	Email from L. Hsu to A. Koch, et al., re: Analyzing Litigation Success Rates (Jan. 15, 2010), with attachments	Jan. 15, 2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-473	Supplemental Expert Report of Anthony Lowman, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv- 831 (D.N.J.) (Jan. 26, 2010)	01/26/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-474	Complaint, Endo Pharms. Inc. v. Roxane Labs. Inc., No. 2:10-cv-534 (D.N.J.) (Jan. 29, 2010)	01/29/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-475	Rebuttal Expert Report of Edmund J. Elder, Jr., Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-476	Expert Report of Terrence Blaschke, M.D. in Rebuttal to the Report of Danny D. Shen, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-477	Expert Report of Reza Fassihi, PH.D. in Rebuttal to the Report of Edmund J. Elder, Jr., Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-478	Expert Report of Reza Fassihi, PH.D. in Rebuttal to the Report of Arthur H. Kibbe, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-479	Expert Report of Jason T. McConville, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-480	Rebuttal Expert Report of Charles E. McCulloch, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-481	Expert Report of Edgar L. Ross, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-482	Expert Report of John S. Russell, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Feb. 1, 2010)	02/01/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-483	Order on Claim Construction, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Mar. 30, 2010)	03/30/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	In Camera Status
RX-484	Amended Order on Claim Construction, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (Apr. 5, 2010)	04/05/2010	N/A	N/A	CX2766	JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-485	Notice of Settlement, Endo Pharms. Inc. v. Barr Labs., Inc., No. 2:09-cv-3224 (D.N.J.) (Apr. 15, 2010)	04/15/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-487	Order, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (May 26, 2010)	05/26/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-488	Stipulation of Dismissal and Order, Endo Pharms. Inc. v. Impax Labs. Inc., No. 2:09-cv-831 (D.N.J.) (June 15, 2010)	06/15/2010	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-489	Consent Order and Stipulated Injunction, Endo Pharms. Inc. v. Sandoz Inc., No. 2:09-cv-836 (D. Del.) (June 15, 2010)	06/15/2010	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-490	Impax Laboratories, Inc., Annual Report (Form 10-K) (Feb. 25, 2011)	02/25/2011	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-491	Endo Pharmaceuticals Holdings Inc., Annual Report (Form 10-K) (Feb. 28, 2011)	02/28/2011	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-492	Stipulated Order of Dismissal, Endo Pharms. Inc. v. Roxane Labs. Inc., No. 2:10-cv-534 (D.N.J.) (May 11, 2011)	05/11/2011	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-493	Endo Pharmaceuticals Holdings Inc., Form 10-Q (June 30, 2011)	06/30/2011	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-494	Endo Pharmaceuticals Holdings Inc., Form 8-K (May 1, 2012)	05/01/2012	N/A	N/A		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-495	Complaint, Endo Pharms. Inc. v. Actavis Inc., No. 1:12-cv-8985 (S.D.N.Y.) (Dec. 11, 2012)	12/11/2012	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-497	Complaint, Endo Pharms. Inc. v. Mallinckrodt LLC, No. 1:13-cv-3286 (S.D.N.Y.) (May 15, 2013)	05/15/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-498	Complaint, Endo Pharms. Inc. v. Par Pharm. Cos. Inc., No. 1:13-cv-3284 (S.D.N.Y.) (May 15, 2013)	05/15/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-499	Complaint, Endo Pharms. Inc. v. Roxane Labs. Inc., No. 1:13-cv-3288 (S.D.N.Y.) (May 15, 2013)	05/15/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-500	Complaint, Endo Pharms. Inc. v. Sandoz Inc., No. 1:13-cv-3287 (S.D.N.Y.) (May 15, 2013)	05/15/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-501	Complaint, Endo Pharms. Inc. v. Teva Pharms. Inc., No. 1:13-cv-3285 (S.D.N.Y.) (May 15, 2013)	05/15/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-502	Press Release, Pfizer Obtains \$2.15 Billion Settlement from Teva and Sun for Infringement of Protonix Patent, Pfizer (June 12, 2013)	06/12/2013	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-503	Complaint, Endo Pharms. Inc. v. Ranbaxy Labs. Ltd., No. 1:13-cv-4343 (S.D.N.Y.) (June 21, 2013)	06/21/2013	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-504	Opinion, Endo Pharms. Inc. v. Actavis Inc., No. 2013- 1658 (Fed. Cir.) (Mar. 31, 2014)	03/31/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-507	Complaint, Endo Pharms. Inc. v. Actavis Inc., No. 1:14-cv-1381 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-508	Complaint, Endo Pharms. Inc. v. Sandoz, Inc., No. 1:14-cv-1388 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-509	Complaint, Endo Pharms. Inc. v. Amneal Pharms., LLC., No. 1:14-cv-1382 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-510	Complaint, Endo Pharms. Inc. v. Impax Labs., Inc., No. 1:14-cv-1383 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-511	Complaint, Endo Pharms. Inc. v. Impax Labs., Inc., No. 1:14-cv-1384 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-512	Complaint, Endo Pharms. Inc. v. Teva Pharms. USA, Inc., No. 1:14-cv-1389 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-513	Complaint, Endo Pharms. Inc. v. Par Pharm. Cos., Inc., No. 1:14-cv-1385 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-514	Complaint, Endo Pharms. Inc. v. Ranbaxy Labs. Ltd., No. 1:14-cv-1386 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-515	Complaint, Endo Pharms. Inc. v. Roxane Labs., Inc., No. 1:14-cv-1387 (D. Del.) (Nov. 7, 2014)	11/07/2014	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-522	Findings of Fact and Conclusions of Law, Endo Pharms. Inc. v. Actavis Inc., No. 1:12-cv-8985 (S.D.N.Y.) (Aug. 18, 2015)	08/18/2015	N/A	N/A	CX3239	JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-523	Order Adopting Report and Recommendation, Endo Pharms. Inc. v. Actavis Inc., No. 1:14-cv-1381 (D. Del.) (Nov. 17, 2015)	11/17/2015	N/A	N/A	CX3238	JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-525	Omnibus Opinion, Endo Pharms. Inc. v. Actavis Inc., No. 1:12-cv-8985 (S.D.N.Y.) (Apr. 29, 2016)	04/29/2016	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay	Tr. 1956:7 - 1958:25	
RX-528	Amended Judgment, Endo Pharms. Inc. v. Actavis Inc., No. 1:12-cv-8985 (S.D.N.Y.) June 29, 2016)	06/29/2016	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-531	Final Judgment, Endo Pharms. Inc. v. Teva Pharms. USA, Inc., No. 1:14-cv-1389 (D. Del.) (Nov. 30, 2016)	11/30/2016	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-544	Trial Opinion, Endo Pharms. Inc. v. Actavis Inc., No. 1:14-cv-1381 (D. Del.) (Aug. 30, 2017)	08/30/2017	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay	Tr. 1964:21 - 1966:16	
RX-545	2017 Cigna Comprehensive Drug List (Formulary) (Sept. 1, 2017)	09/01/2017	N/A	N/A		Nov. 7, 2017 ⁷	Non-hearsay	Tr. 2136:8 - 2145:19	
RX-547	Rebuttal Expert Report of Sumanth Addanki, Ph.D. (Sept. 5, 2017)	09/05/2017	N/A	N/A		JX-002 (Oct. 24, 2017)		Tr. 2196:12 - 2197:1 Tr. 2245:7 - 2250:7 Tr. 2275:25 - 2279:23 Tr. 2309:23 - 2328:7 Tr. 2333:1 - 2337:14 Tr. 2429:3 - 2440:8	

⁷ Admitted on November 7, 2017 during the testimony of Dr. Edward Michna. (See Tr. 2140.)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay ¹	Discussed	In Camera Status
								Tr. 2445:1 - 2448:4 Tr. 2449:18 - 2450:16 Tr. 2452:23 - 2453:5 Tr. 2456:5 - 2456:25 Tr. 2463:12 - 2466:1 Tr. 2484:8 - 2485:10 Tr. 2489:25 - 2495:23 Tr. 2503:8 - 2503:24	
RX-548	Expert Report of E. Anthony Figg (Sept. 5, 2017)	09/05/2017	N/A	N/A		JX-002 (Oct. 24, 2017)		Tr. 1878:6 - 1882:14 Tr. 1894:2 - 1894:20 Tr. 1945:22 - 1946:11 Tr. 1990:10 - 1992:1 Tr. 2015:16 - 2017:11 Tr. 2027:9 - 2028:8 Tr. 2058:12 - 2059:21	
RX-549	Expert Report of Edward Michna, M.D. (Sept. 5, 2017)	09/05/2017	N/A	N/A		JX-002 (Oct. 24, 2017)		Tr. 2132:11 - 2134:4 Tr. 2167:18 - 2170:8	
RX-550	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Aug. 30, 2017)	08/30/2017	N/A	N/A		JX-002 (Oct. 24, 2017)			
RX-552	IMS Health NDTI Data		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-553	IMS_NPA_2003-2008		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-554	IMS Health Channel Dynamics Data		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-555	MMIT Formulary Data		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-556	Truven RedBook		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay ¹	Discussed	In Camera Status
RX-557	MMIT		N/A	N/A		JX-002 (Oct. 24, 2017)			Granted (Oct. 23, 2017)
RX-558	Endo Executive Summary (Q2 2010)	06/30/2010	EPI000286600	EPI000286603		JX-002 (Oct. 24, 2017)			Granted (Oct. 20, 2017)
RX-559	Email from D. Rudo to D. Lake re: Coupon Entries (Feb. 8, 2010), with attachments	02/08/2010	EPI000473130	EPI000473134		JX-002 (Oct. 24, 2017)			
RX-560	Email from M. Collins to N. Fetrow, et al., re: EXTERNAL Endo 2014 Posters SOW for Review (Oct. 30, 2013), with attachments	10/30/2013	EPI000731497	EPI000731502		JX-002 (Oct. 24, 2017)			
RX-561	Spreadsheet, Endo Contribution Margin Report (June 11, 2014)	06/11/2014	EPI000731512	EPI000731512		JX-002 (Oct. 24, 2017)			
RX-562	Spreadsheet, Endo Contribution Margin Report (June 11, 2014)	06/11/2014	EPI000731514	EPI000731514		JX-002 (Oct. 24, 2017)			
RX-563	Email from Communications to Endo Employees, et al., re: Important Announcement from Julie McHugh, COO, Regarding Endo Product Supply Disruption and Possibility of Rare Tablet Mix-up (Jan. 9, 2012)	01/09/2012	EPI000740345	EPI000740346		JX-002 (Oct. 24, 2017)			
RX-564	Email from A. Koch to T. Smolenski re: Oxy (Jan. 7, 2011)	01/07/2011	IMPAX-OPANA-CID00003535	IMPAX-OPANA-CID00003536		JX-002 (Oct. 24, 2017)			
RX-565	Email from C. Mengler to A. Levin, et al., re: Highly Confidential - Rule 408 Settlement Communication (May 27, 2010)	05/27/2010	IMPAX-OPANA-CID00006361	IMPAX-OPANA-CID00006362	CX2988	JX-002 (Oct. 24, 2017)		Tr. 3023:23 - 3026:20	
RX-566	Email from T. Smolenski to T. Engle, et al., re: Oxycodone and Oxymorphone (Oct. 6, 2010)	10/06/2010	IMPAX-OPANA-CID00007149	IMPAX-OPANA-CID00007149		JX-002 (Oct. 24, 2017)			

In the Matter of Impax Laboratories, Inc.
Docket No. 9373

PUBLIC

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admitted	Non-Hearsay¹	Discussed	<i>In Camera</i> Status
RX-568	Email from L. Hsu to M. Donahue, et al., re: Research Note - ENDO First Settlement for Generic Opana ER (Feb. 23, 2009)	02/23/2009	IMPAX-OPANA-CID00020814	IMPAX-OPANA-CID00020814		JX-002 (Oct. 24, 2017)			
RX-570	Impax Generic Business Board of Directors Meeting (May 14, 2013)	05/14/2013	Impax_Opana_PartIII_0081824	Impax_Opana_PartIII_0081856		JX-002 (Oct. 24, 2017)			
RX-571	Email from A. Koch to L. Hsu, et al., re: NPC e-mail Vote on Opana ER's New Strengths (Mar. 3, 2008)	03/03/2008	IMPAX-OPANA-CID00018151	IMPAX-OPANA-CID00018151		JX-002 (Oct. 24, 2017)			
RX-572	Email from A. Koch to L. Hsu et al., re Close (June 6, 2010).	06/06/2010	IMPAX-OPANA-CID00019470	IMPAX-OPANA-CID00019470		JX-002 (Oct. 24, 2017)			
RX-573	Meeting invite between Impax and Endo RE: Draft Impax/Endo/Penwest Settlement and License (June 7, 2010), with attachments	06/07/2010	IMPAX-OPANA-CID00023684	IMPAX-OPANA-CID00023708		JX-002 (Oct. 24, 2017)			
RX-574	Impax Motion In Endo v. FDA, No. 1:12-cv-01936 (Dec. 9, 2012).	12/09/2012	N/A	N/A		JX-002 (Oct. 24, 2017)	Non-hearsay		
RX-575	Final Judgment, <i>Endo Pharm., Inc. v. Actavis LLC</i> , No. 1:14-cv-1381-RGA (D. Del. Sept. 15, 2017)	09/15/2017	N/A	N/A		Nov. 6, 2017 ⁸	Non-hearsay	Tr. 1966:17 - 1970:2	

⁸ Admitted during the testimony of E. Anthony Figg on November 6, 2017. (See Tr. 1969.)

Notice of Electronic Service

I hereby certify that on January 04, 2018, I filed an electronic copy of the foregoing Respondent's Exhibit Index, with:

D. Michael Chappell
Chief Administrative Law Judge
600 Pennsylvania Ave., NW
Suite 110
Washington, DC, 20580

Donald Clark
600 Pennsylvania Ave., NW
Suite 172
Washington, DC, 20580

I hereby certify that on January 04, 2018, I served via E-Service an electronic copy of the foregoing Respondent's Exhibit Index, upon:

Bradley Albert
Attorney
Federal Trade Commission
balbert@ftc.gov
Complaint

Daniel Butrymowicz
Attorney
Federal Trade Commission
dbutrymowicz@ftc.gov
Complaint

Nicholas Leefer
Attorney
Federal Trade Commission
nleefer@ftc.gov
Complaint

Synda Mark
Attorney
Federal Trade Commission
smark@ftc.gov
Complaint

Maren Schmidt
Attorney
Federal Trade Commission

mschmidt@ftc.gov
Complaint

Eric Sprague
Attorney
Federal Trade Commission
esprague@ftc.gov
Complaint

Jamie Towey
Attorney
Federal Trade Commission
jtowey@ftc.gov
Complaint

Chuck Loughlin
Attorney
Federal Trade Commission
cloughlin@ftc.gov
Complaint

Alpa D. Davis
Attorney
Federal Trade Commission
adavis6@ftc.gov
Complaint

Lauren Peay
Attorney
Federal Trade Commission
lpeay@ftc.gov
Complaint

James H. Weingarten
Attorney
Federal Trade Commission
jweingarten@ftc.gov
Complaint

Edward D. Hassi
O'Melveny & Myers, LLP
ehassi@omm.com
Respondent

Michael E. Antalics
O'Melveny & Myers, LLP
mantalics@omm.com
Respondent

Benjamin J. Hendricks
O'Melveny & Myers, LLP
bhendricks@omm.com
Respondent

Eileen M. Brogan
O'Melveny & Myers, LLP
ebrogan@omm.com
Respondent

Anna Fabish
O'Melveny & Myers, LLP
afabish@omm.com
Respondent

Stephen McIntyre
O'Melveny & Myers, LLP
smcintyre@omm.com
Respondent

Rebecca Weinstein
Attorney
Federal Trade Commission
rweinstein@ftc.gov
Complaint

Garth Huston
Attorney
Federal Trade Commission
ghuston@ftc.gov
Complaint

I hereby certify that on January 04, 2018, I served via other means, as provided in 4.4(b) of the foregoing Respondent's Exhibit Index, upon:

Markus Meier
Attorney
Federal Trade Commission
mmeier@ftc.gov
Complaint

Eileen Brogan
Attorney